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Abstract 
 
Ionizing radiation is known to initiate apoptosis in mammalian cells by causing the 
transformation of cytochrome c into a peroxidase, which results in the specific peroxidation of 
the mitochondrial phospholipid cardiolipin. Here we report the design and synthesis of 8 
imidazole fatty acid derivatives that bind to the cyt c:CL complex and inhibit the peroxidase 
activity required for the initiation of apoptosis. We postulate that imidazole acts as a sixth ligand 
to the haem iron and stops the interaction with H2O2. Two mitochondrially directed analogues (3-
hydroxypropyl)triphenylphosphonium esters) of 12-imidazole-stearic acid and 12-imidazole-
oleic acid not only were demonstrated to be peroxidase inhibitors in vitro, but were also 
extraordinarily effective in protecting mice from lethal doses (9 Gy) of ionization radiation. We 
studied the structure activity relationship to a group of triphenyl phosphonium derivatives 
containing imidazole at different positions on the fatty acid chain, and observed that the C8-
imidazole stearate analogue had marginally better activity than the others. But overall, the 
structure activity result were remarkable “flat” with all compounds prepared having rather 
similar inhibitory strength. We also synthesized carnitine mono and di-esters of 12-imidazole 
fatty acids but full biological data is not yet available for these compounds. 
 
 
 
 
 
 
iv 
 
Table of Contents 
 
Acknowledgements……………………………………………………………………………ii 
Abstract……………………………………………………………………………………….iii 
List of Abbreviations……………………………………………………………………....…ix 
List of Schemes………………………………………………………………………………..x 
List of Figures………………………………………………………………………………....x 
 
1. Introduction……………………………………………………………………………....1 
1.1 Apoptosis……………………………………………………………………………...2 
1.2 Morphological changes of apoptosis….………………………………………………3 
1.3 Mitochondria…………………………………………………………………………..4 
1.4 Mitochondria and cell death…………………………………………………………..5 
1.5 Reactive oxygen species (ROS)……………………………………………………….5 
1.6 Cytochrome c………………………………………………………………………….8 
1.7 Cardiolipin (CL)……………………………………………………………………….9 
1.8 Aim & objectives…………………………………………………………………….11 
2. Results and Discussion………………………………………………………………….15 
2.1 Synthesis of positional isomers of imidazole substituted C18 fatty acids esters…….15 
2.2.1 Synthesis of (S,Z)-(3-((12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)propyl) 
triphenylphosphonium bromide  (TPP-12-IOA)…...……………………………………19 
v 
 
2.2.2 Synthesis of (3-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-12-ISA)……...……………………………………………20 
2.2.3 Biological results of TPP-12-IOA and TPP-12-ISA..…………………………….21 
2.3.1 Synthesis of (3-((6-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl) 
triphenylphosphonium bromide (TPP-6-ISA)……………….………………………….23 
2.3.2 Synthesis of (3-((8-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl) 
triphenylphosphonium bromide (TPP-8-ISA)……………….………………………….25 
2.3.3 Biological results of compounds TPP-6-ISA and TPP-8-ISA………..…………..26 
2.4 Synthesis of (3-((10-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl) 
triphenylphosphonium bromide (TPP-10-ISA)…...…………………………………….27 
2.4.1 Synthesis of (3-((13-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-13-ISA)…...………………………………………………29 
2.4.2 Synthesis of (3-((14-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-14-ISA)...…………………………………………………30 
2.4.3 Biological results of compounds TPP-6-ISA, TPP-8-ISA, TPP-10-ISA,  
TPP-12-ISA, TPP-13-ISA and TPP-14-ISA……..………………...…………………..32 
2.5.1 Synthesis of Carnitine esters of IFAs………………………………………………33 
2.5.2 Synthesis of mono(2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-3-
carboxy-N,N,N-trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate)  
monochloride (CSE-12-IOA) and mono(2-((12-(1H-imidazol-1-yl) 
octadecanoyl)oxy)-3-carboxy-N,N,N-trimethylpropan-1-aminium) mono(2,2,2-
trifluoroacetate) monochloride (CSE-12-ISA) ………………………………………….33 
2.5.3 Biological results of CSE-12-IOA and CSE-12-ISA ……………...……………..35 
vi 
 
2.6 Synthesis of 2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-4-methoxy-N,N,N-
trimethyl-4-oxobutan-1-aminium iodide (CDE-12-IOA)  and 2-((12-(1H-imidazol-1-
yl)octadecanoyl)oxy)-4-methoxy-N,N,N-trimethyl-4-oxobutan-1-aminium iodide (CDE-
12-ISA)…………………………………………………………………………………..39 
3. Conclusion and Future Work……………………………………………………………….41 
4. Experimental…………………………………………………………………………………42 
General…………………………………………………………………………………...41 
Synthesis of (R,Z)-methyl 12-(1H-imidazol-1-yl)octadec-9-enoate (2)…………………42 
Synthesis of (S, Z)-12-(1H-imidazol-1-yl)octadec-9-enoic acid (3) ……………………43 
Synthesis of (3-hydroxypropyl)triphenylphosphonium bromide (5)…………………….45 
Synthesis of (S,Z)-(3-((12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)propyl) 
triphenylphosphonium bromide (TPP-12-IOA)………………………………………....45 
Synthesis of methyl 12-(1H-imidazol-1-yl)octadecanoate (7)………………………..…46 
Synthesis of 12-(1H-imidazol-1-yl)octadecanoic acid (8)……………………………….47 
Synthesis of (3-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl 
phosphonium bromide (TPP-12-ISA)…………………………………………………...48 
Synthesis of methyl 6-oxohexanoate (10)………………………………………………..49 
Synthesis of methyl 6-hydroxyoctadecanoate (11)………………………………………50 
Synthesis of methyl 6-(1H-imidazol-1-yl)octadecanoate (12)…………………………..52 
Synthesis of 6-(1H-imidazol-1-yl)octadecanoic acid (13)…………………….................53 
Synthesis of (3-((6-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl 
phosphonium bromide (TPP-6-ISA)………………………………………..…………...54 
Synthesis of methyl 8-oxooctanoate (15)………………………………………………..55 
vii 
 
Synthesis of methyl 8-hydroxyoctadecanoate (16)……………………………………....56 
Synthesis of  methyl 8-(1H-imidazol-1-yl)octadecanoate (17)………………………….57 
Synthesis of 8-(1H-imidazol-1-yl)octadecanoic acid (18)……….………………………58 
Synthesis of (3-((8-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl- 
phosphonium bromide (TPP-10-ISA)…………………………………………………...59 
Synthesis of  10-(benzyloxy)decan-1-ol (20)……………………………………………60 
Synthesis of 10-(benzyloxy)decanal  (21)……………………………………………….60 
Synthesis of 18-(benzyloxy)octadecan-9-ol (22)………………………………………...61 
Synthesis of 1-(18-(benzyloxy)octadecan-9-yl)-1H-imidazole (23)…………………….62 
Synthesis of 10-(1H-imidazol-1-yl)octadecan-1-ol (24)………………………………...63 
Synthesis of 10-(1H-imidazol-1-yl)octadecanoic acid (25)……………………………...64 
Synthesis of (3-((10-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl 
phosphonium bromide (TPP-10-ISA)………………………………………………...…65 
Synthesis of 12-bromododecan-1-ol (27)…………………………………………..……66 
Synthesis of 12-bromododecanal (28)…………………………………………………...67 
Synthesis of 17-bromoheptadecan-6-ol (29)……………………………………………..68 
Synthesis of 13-hydroxyoctadecanenitrile (30)………………………………………….69 
Synthesis of  13-(1H-imidazol-1-yl)octadecanenitrile (31)……………………………...69 
Synthesis of 13-(1H-imidazol-1-yl)octadecanoic acid (32)……………………………...70 
Synthesis of (3-((13-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl 
phosphonium bromide (TPP-13-ISA)…………………………………………………...71 
Synthesis of diethyl 2-(12-hydroxydodecyl)malonate (33)………………………….......72 
Synthesis of diethyl 2-(12-oxododecyl)malonate (34)…………………………………..73 
viii 
 
Synthesis of diethyl 2-(12-hydroxyhexadecyl)malonate (35)..…………………………..74 
Synthesis of diethyl 2-(12-(1H-imidazol-1-yl)hexadecyl)malonate (36)………………..75 
Synthesis of 14-(1H-imidazol-1-yl)octadecanoic acid (37)……………………………...76 
Synthesis of (3-((14-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl 
phosphonium bromide (TPP-14-ISA)…………………………………………………...77 
Synthesis of mono(2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-3- 
carboxy-N,N,N-trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate) 
 monochloride (CSE-12-IOA)…………………………………………………………...78 
Synthesis of mono(2-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)-3-carboxy- 
N,N,N-trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate) 
 monochloride (CSE-12-ISA)………………………………………………………...….80 
Synthesis of 2-hydroxy-4-methoxy-N,N,N-trimethyl-4-oxobutan-1- 
aminium iodide (41)……………………………………………………………………...81 
Synthesis of 2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-4- 
methoxy-N,N,N-trimethyl-4-oxobutan-1-aminium iodide (CDE-12-IOA)……………..82 
Synthesis of 2-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)-4-methoxy- 
N,N,N-trimethyl-4-oxobutan-1-aminium iodide (CDE-12-ISA)………………………...83 
5. References………………………………………………………………………………….…85 
 
 
 
 
 
ix 
 
List of Abbreviations 
 
Ac   Acetyl 
DCC   N,N'-Dicyclohexylcarbodiimide 
DCM   Dichloromethane 
DCU   N,N'-Dicyclohexylurea 
DMAP   4-(Dimethylamino)pyridine 
DMF   N,N-Dimethylformamide 
EtOAc   Ethyl acetate 
EtOH   Ethanol 
FAB   Fast Atom Bombardment 
HRMS   High Resolution Mass Spectrometry 
MeOH   Methanol 
MS   Mass Spectroscopy 
MsCl   Methanesulfonyl Chloride 
NMR   Nuclear Magnetic Resonance  
RT   Room Temperature 
TEA   Triethylamine 
THF   Tetrahydrofuran 
TLC   Thin Layer Chromatography 
TPP   Triphenylphosphine  
TFA   Trifluoroacetic Acid 
x 
 
List of Schemes 
 
Scheme 1: Synthesis of TPP-12-IOA…………………………………………………………...19 
Scheme 2: Synthesis of TPP-12-ISA……………...…………………………………………….20 
Scheme 3: Synthesis of TPP-6-ISA………………………………..……………………………24 
Scheme 4: Synthesis of TPP-8-ISA…………………………………..………………………....25 
Scheme 5: Synthesis of TPP-10-ISA…………………………………………………………....28 
Scheme 6: Synthesis of TPP-13-ISA……………………………………………………………29 
Scheme 7: Synthesis of TPP-14-ISA……………………………………………………………31 
Scheme 8: Synthesis of CSE-12-IOA and CSE-12-ISA……….……………………………….34 
Scheme 9: Synthesis of CDE-12-IOA and CDE-12-ISA……………………………………….39 
 
List of Figures 
 
Figure 1: Steps involved in the process of apoptotic and necrotic cell death…………………..…4 
Figure 2: Redox processes in the presence of Fe3+…………………………………………….…6 
Figure 3: Role of ROS in apoptosis induction and source and target of mitochondria…………...7 
Figure 4: Human Cytochrome c protein………………………………………………………......8 
Figure 5: Structure of cardiolipin, where Rn is 18-carbon chain fatty acid……………………….9 
Figure 6: Structures of IOA, ISA, IEOA and IDA……………………………………………...12 
Figure 7: Structures of TPP-12-IOA and TPP-12-ISA ………………………………………...13 
Figure 8: General scheme for different positional imidazole derivatives………………………..13 
Figure 9: Structures of the carnitine esters CSE-12-IOA and CSE-12-ISA…………………….14 
xi 
 
Figure 10: Structures of the carnitine double esters CDE-12-IOA and CDE-12- ISA………... 14 
Figure 11: Oxidation of Amplex Red to resorufin…………………………………………….…16 
Figure 12: Inhibition of peroxidase activity of cyt c/TOCL complexes with IEOA, IOA, ISA, 
      and IDA………..……………………………………………...……………………..16 
Figure 13: Docked modeling for the binding of IOA on cytochrome c…………………………17 
Figure 14: Radiation protection and mitigation by TPP-12-IOA and TPP-12-ISA………….....21 
Figure 15: TPP-imidazole-stearic acid derivatives (TPP-ISAs) inhibit peroxidase activity  
      of  cyt c/TOCL complexes. New derivatives: TPP-6-ISA, 
                 TPP-8-ISA and TPP-12-ISA……………………………………………………...…26 
Figure 16: Effect of TPP- imidazole-stearic acid (TPP-ISA) derivatives on peroxidase activity of 
                 cyt c/TOCL complexes assessed by H2O2-dependent oxidation of Amplex         
      Red……………………………………………………………………………….…...32  
Figure 17: Cytotoxicity of TPP or carnitine conjugated fatty acid in mouse embryonic cells…..35 
Figure 18: Radiomitigative effect of TPP or carnitine conjugated fatty acid in 
                 mouse embryonic cells………………………………………………………………..36 
Figure 19: Cytotoxicity of carnitine conjugated imidazole fatty acids (CISFA and CIOFA) 
                  in mouse embryonic cells…………………………………………………….............37 
Figure 20: Radiomitigative effects of carnitine conjugated imidazole fatty acids in  
                  mouse embryonic cells………………………………………………………………38 
 
 
 
1 
 
1. Introduction 
 
The March 11
th
, 2011 earthquake and tsunami in Japan caused extensive damage to the 
Fukushima Daiichi nuclear power generating station.
 This disaster brought to the public‟s 
attention the very serious concerns of human exposure to ionizing radiation. However, humans 
are exposed to radiation in other ways: airplane flight crews are exposed to cosmic radiation 
during high altitude flights, and patients receiving radiation therapy for solid tumours can be 
received very high doses of focused radiation on particular tissues. Ionizing radiation induces 
controlled, or programmed, cell death process called apoptosis.
1
 This is thought to be initiated by 
the generation of reactive oxygen species (ROS).
2 
Unfortunately, during the irradiation of tumour 
cells, normal cells are also affected, leading to the loss of non-diseased tissue. Cancer patients 
have been treated with electromagnetic radiation (photons), such as X-rays and gamma rays, and 
particulate radiation, usually electrons and, to a lesser extent, neutrons and protons.
3
 There are no 
effective solutions to protect non-cancerous cells from the damaging effects of ionizing 
radiation.    
 
It has been shown that the concentrations of vitamins C and E in mice bone marrow were 
reduced following total body exposure to X-ray radiation.
4
 Radiation induced apoptosis in cancer 
radiotherapy was reduced by antioxidants, vitamins E and C, phytochemicals and micronutrients 
like selenium.
5
 Antioxidant phytochemicals, including ﬂavonoids, polyphenols, carotenoids and 
organosulfur compounds, have been shown to have varying degrees of effectiveness as radio-
protective substances.
6,7
  
 
There is a need to understand the biological mechanisms of radiation-induced apoptosis.  
Radiation affected cells undergo apoptosis by several mechanisms. Induction of apoptosis by 
2 
 
ionizing radiation can occur in different cellular compartments, including the nucleus, cytosolic 
elements (organelles) and the plasma membrane
8
 and the generation of reactive oxygen species 
(ROS) is thought to be a common initiating event.  
 
1.1 Apoptosis 
The word „„apoptosis‟‟ is from the ancient Greek words apo - from/off/without, and ptosis – 
falling.
9
 The term “apoptosis” was first introduced by John Kerr in 1972.10 It refers to the 
formation in a cell, under various initiating causes, of a morphological feature called “apoptotic 
bodies”.11,12 The German scientist Carl Vogt described the principle of apoptosis in 184213 and 
the anatomist Walther Flemming presented a more precise description of the process of 
programmed cell death in 1885.
14
 Sydney Brenner, H. Robert Horvitz and John E. Sulston jointly 
received the Nobel Prize for Medicine or Physiology in the year of 2002 for their discovery on 
gene regulation of organ development and programmed cell death or apoptosis in the nematode 
Caenorhabditis elegans.  
 
Cell death by apoptosis is an active process. It plays a key role in the development of 
multicellular organisms. Cells that have been produced in excess during early growth and 
development can undergo programmed cell death to contribute to the forming of organs and 
tissues.
13 
Apoptosis regulates and maintains cell populations in tissues during both normal 
physiological and pathological conditions.
15
 In the human body around 100,000 cells are 
produced each second by the process of mitosis and the same number of cells die by the process 
of apoptosis.
16 
During the development of the brain, half of the neurons that are initially formed 
will die by the time the adult brain is formed.
13, 17
   
 
3 
 
Damage to healthy cells can also cause apoptosis. For instance, if a cell‟s DNA is damaged to 
some extent, then it will try to repair it. If the cell is unable to repair the damaged DNA, then 
apoptosis may be initiated. Such a process is a protection against cancer since cells with 
damaged DNA can lose control of growth processes and may turn cancerous. 
 
Scientists have shown great interest in apoptosis since a number of diseases are known to be 
caused or complicated by increased levels of apoptosis, including degenerative diseases such as 
Parkinson‟s, Alzheimer‟s, spinal muscular atrophy and AIDS. Decreased levels of apoptosis are 
known to be involved in cancer (DNA mutations in critical control proteins such as p53 and Bcl-
2) or autoimmune diseases (type I diabetes or encephalomyelitis). Apoptosis can also be 
triggered by toxins and other cellular stresses such as oxidative stress or alcohol.
11
 
 
1.2 Morphological changes of apoptosis 
Apoptotic cells can be identified by a distinct set of biochemical and physical changes.
15
 During 
early stages of apoptosis, the apoptotic cell shrinks, shows membrane deformations and loses 
contact from the neighbouring cells. Its chromatin condenses and marginates to the nuclear 
membrane. As the process continues, the plasma membrane shows distinct blebing and budding. 
Finally, the cell is divided into compact membrane-enclosed structures called “apoptotic” bodies.  
These bodies have cytosol, the condensed chromatin and organelles. These are shown in the 
Figure 1. Macrophages engulf the apoptotic bodies and these apoptotic bodies are removed from 
the tissue without causing an inflammatory response.   
 
Cells can also die via necrosis, usually after suffering a major physiological insult.
18
 This results 
in a loss of membrane integrity, swelling and breakup of the cells. The release of cellular 
contents into the surrounding environment can be observed during necrosis. This can damage the 
4 
 
surrounding cells and initiate a strong inflammatory response within the tissue.
18 
Figure 1 shows 
the generalized pathways involved in the processes of apoptosis and necrosis.  
 
 
Figure 1: Steps involved in the process of apoptotic and necrotic cell death.
15
  
 
Cellular shrinking, chromatin condensation and margination at the nuclear periphery are 
observed in apoptosis, followed by the eventual formation of membrane-bound apoptotic bodies 
that contain organelles, cytosol and nuclear fragments which are phagocytosed without triggering 
inflammatory processes. During necrosis, the cell swells, becomes leaky, and finally is disrupted 
and releases its contents into the surrounding tissue resulting in inflammation.
15,19 
 
 
 
1.3 Mitochondria  
 
The word mitochondrion is derived from the Greek words mitos (μίτος) meaning thread, and 
chondrion (χονδρίον) meaning granule. Most eukaryotic cells contain mitochondria which are 
absent from prokaryotic cells. A mitochondrion is an organelle with inner and outer 
membranes.
20
 The size of these organelles range from 0.5 to 1.0 μm in diameter. Mitochondria 
5 
 
are cellular power plants within the cell, converting high chemical potential molecules such as 
fatty acids and sugars, into more usable chemical forms such as adenosine triphosphate (ATP).
21
 
Mitochondria are also involved in a wide range of other processes like cell signalling, cellular 
differentiation, cell death, as well as the control of the cell cycle and cell growth.
22
 It is also now 
becoming increasingly clear that it is in the mitochondria where the first key steps occur that lead 
a cell down the apoptotic cascade.
23 
 
1.4 Mitochondria and cell death 
There are three general mechanisms by which mitochondria can participate in the initiation and 
promotion of apoptosis, and these effects might be interrelated with each other. These 
mechanisms are: (i) change of cellular reduction-oxidation (redox) potential, (ii) disruption of 
electron transport, oxidative phosphorylation, and adenosine triphosphate (ATP) synthesis and 
(iii) release of proteins that trigger activation of the caspase family of proteases.
1 
 
1.5 Reactive oxygen species (ROS)  
Reactive oxygen species (ROS) are short-lived diffusible species that include hydroxyl (HO•), 
alkoxyl (RO•) and peroxyl (ROO•) radicals.  Some radicals, such as superoxide (O2
•-
) and 
nitroxyl radical (NO•) species, have long lifetimes of many seconds to minutes. The non-radicals 
hydrogen peroxide (H2O2), organic hydroperoxides (ROOH) and hypochlorous acid (HOCl) are 
also included in ROS. ROS can damage both DNA and proteins.
24 
ROS may also act as chemical 
messengers. H2O2 is a secondary messenger
25
 that is involved in receptor-mediated signalling 
pathways and transcriptional activation.
26
 Hydrogen peroxide has been shown to induce 
apoptosis and this induction was prevented by catalase. 
27 
 
6 
 
During the transfer of electrons to molecular oxygen during oxidative phosphorylation, an 
estimated 1 to 2% of electrons in the respiratory chain lose their way, most of them participating 
in formation of ROS.
28
 The production of superoxide can be increased by anything that decreases 
the coupling efficiency of the electron transport chain.
1
 Increased superoxide formation can lead 
to increased lipid peroxidation which is generally accepted to be an early chemical event in 
apoptosis.
29
 Manganese superoxide dismutase converts superoxide anion O2
.-
  into H2O2 and O2,  
In the presence of transition metals such as iron (Fe
3+
), hydrogen peroxide can be converted to 
hydroxyl radical via Fenton chemistry.
30
 This process has been shown in the Figure 2.    
 
 
 
Figure 2: Redox processes in the presence of Fe
3+
. 
 
 
If a sequential process is assumed, initial released ROS from mitochondria can directly or 
indirectly (via ceramide generation) increase the gating potential of the pore (Figure 3) on 
mitochondria, rendering mitochondria both as a source and target of ROS.
24
 The major sources 
of superoxide anion production in cells are mitochondria. Release of cyt c seems to be the 
significant event
1
 in apoptosis initiation, as it is a required step for aggregation of the adapter 
molecule Apaf1. The pro-apoptotic member of the Bcl-2 family Bax protein is responsible for 
Fe3+   +  O2
•- Fe2+   +   O2
Fe2+  +  H2O2 Fe
3+  +  HO-  +  HO•
O2
•-  +  H2O2 HO
-  +  HO•  +  O2
Fe3+
7 
 
 
Figure 3: Role of ROS in apoptosis induction and source and target of mitochondria.
24
  
 
 
releasing cytochrome c from mitochondria.
31 
Cytochrome c exits from the mitochondrial 
membrane by a pore created by some Bcl–2 family members, including Bax.1 The disruption of 
the mitochondrial potential by ROS and opening of the mitochondrial permeability pore
11
 leads 
to the release of cytochrome c.
32
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1.6 Cytochrome c (cyt c) 
Cytochrome c is a small heme protein having 12 kDa molecular weight. It can be found in the 
inner membrane of the mitochondrion and is loosely associated with it.
33
 Cytochrome c is a 
highly soluble protein, about 100 g/L at pH 7.0. The cyt c contains 104 amino acids and a heme 
group that is covalently bonded to the protein.
34 
The cyt c is a chief component of the electron 
transport chain. It can undergo one-electron oxidation and reduction, but it does not bind to 
oxygen. It transfers electrons between Complexes III (Coenzyme Q - Cyt C reductase) and IV 
(Cyt C oxidase).
35
 The structure of human cytochrome c protein is shown in Figure 4. The 
orange colored iron atom is coordinated with six ligands, the nitrogen atoms from the porphyrin 
ring contribute four ligands, and the sulphur atom of methionine-80 and nitrogen atom of 
histidine-18 residues form the fifth and sixth ligands.  
 
 
Figure 4: Human Cytochrome c protein. 
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1.7 Cardiolipin (CL) 
Cardiolipin (IUPAC name: 1,3-bis(sn-3′-phosphatidyl)-sn-glycerol),  is an important component 
of the mitochondrial inner membrane,  where it comprises about 20% of the total lipid 
composition. CL was first isolated from beef heart in the early 1940s.
36 
Both in mammalian and 
plant cells, CL is found in the inner mitochondrial membrane.
37
 It is an essential component for 
the optimal function of many enzymes which are involved in mitochondrial energy metabolism. 
The generalized structure of cardiolipin is shown in Figure 5.  
 
Figure 5: Structure of cardiolipin, where R1, 2, 3 and  4 are 18-carbon chain fatty acid.  
 
CL is a diphosphatidylglycerol lipid, in which there are three glycerol moieties; two 
phosphatidylglycerols connect with a glycerol backbone to form a dimer. It thus contains four 
acyl groups and two negative charges. Most CL in animal tissues contains 18-carbon fatty acyl 
chains with two unsaturated bonds, called linoleic acid.
38 
The occurrence of these unsaturated 
fatty acids in mitochondria renders it the primary target of attack by free radicals.
39
 
 
CL is found primarily in membranes that also has the F0F1-ATPase. CL is the only eukaryotic 
phospholipid which is synthesized in mitochondria, where it remains until the cell dies. All other 
phospholipids are synthesized in the endoplasmic reticulum. CL has high binding affinity for the 
membrane proteins that are involved in the synthesis of ATP in the mitochondrion.
40  
 
10 
 
CL is in the inner membrane of mitochondria and is found in only small amounts in the rest of 
the cell. CL exists in contact with sites between the outer and inner membranes. The tBid protein 
targets this CL and leads to an increase in negative intrinsic curvature of the membrane, 
destabilizing the bilayer and likely facilitating cyt c leakage.
41
 This step is followed by the 
binding of CL to Bax/BaK, eliciting oligomerization and cristae remodeling that starts the 
destruction of the organelle.
40
 
 
CL can interact with the electron transport chain complexes that are involved in oxidative 
phosphorylation. It is important for optimal activity of the respiratory chain complexes.
42, 43
 CL 
peroxidation is an early event in the release of cytochrome c and caspase activation.
44
 CL can 
play an important role for the integrity and function of the mitochondrial inner membrane and 
also associated with members of the apoptotic machinery including cytochrome c, Bid and 
caspase 8.
45 
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1.8 Aim & objectives 
Cardiolipin (CL) peroxidation is the chief event leading to formation and release of  pro-
apoptotic bodies.
46
 The catalyst for the peroxidation of the CL is cytochrome c (cyt c).
47 
In 
normally functioning mitochondria, CL and cyt c are well separated, but in the initial stage of 
apoptosis, CL and cyt c form a cyt c/CL complex whose redox potential is -400 mV more 
negative than that of intact cyt c.
48
 The cyt c/CL complex is formed by the trans-membrane re-
distribution of CL allowing a physical interaction of CL and cyt c.
47
 The entire process is driven 
by few mitochondrial proteins. The cyt c can have two important interactions with 
phospholipids, one is an electrostatic interaction and other one is a hydrophobic interaction. 
These two kinds of interactions are necessary for cyt c to exhibit peroxidase activity. The 
initiation of apoptosis in irradiated cells is marked by a specific increase in the peroxidation of 
CL. As cyt c/CL complex formation initiates the apoptotic events, we are interested in targeting 
the same complex to stop the activity of the cyt c peroxidase and thus radiation-induced 
apoptosis. The cyt c has a heme-iron that is the catalytic site for peroxidase activity. Upon 
interacting with CL, cyt c partially unfolds and the heme-iron loses a methionine ligand.
49
 
Unfolding of the protein opens a crevice, allowing small molecules such as H2O2 access to the 
heme iron atom. We postulated that locking the heme-iron with specific ligands would stop the 
peroxidase activity of cyt c/CL complex and lead to the inhibition of radiation-induced apoptosis. 
By considering the electrostatic and hydrophobic interactions in the cyt c, our group designed 
imidazole-substituted fatty acids, where imidazole might act as the sixth ligand to the heme iron. 
 
During our initial studies we designed and synthesized (S,Z)-12-(1H-imidazol-1-yl)octadec-9-
enoic acid (IOA), 12-(1H-imidazol-1-yl)octadecanoic acid (ISA), (S,Z)-methyl 12-(1H-imidazol-
1-yl)octadec-9-enoate (IEOA) and 12-(1H-imidazol-1-yl)dodecanoic acid (IDA) (Figure 6).  
12 
 
These compounds were tested and shown to be able to inhibit cyt c peroxidase activity in vitro 
and to a lesser extent in isolated mitochondria. The compound IDA did not show any inhibitor 
activity against cyt c peroxidase activity in vitro and isolated mitochondria. Furthermore, IOA, 
ISA and IEOA could also stop the apoptotic process in cultured cells.  
 
 
 
Figure 6: Structures of IOA, ISA, IEOA and IDA.
46
 
 
We designed and synthesized the TPP-12-IOA and TPP-12-ISA (Figure 7) to target the 
mitochondria, because of the delocalized cationic nature of triphenylphosphonium group 
effectively electrophoresed into the negatively charged mitochondrial membrane. TPP-12-IOA 
and TPP-12-ISA were tested in in vitro and in vivo, and worked both as inhibitors of cyt c 
peroxidase and radiation induced apoptosis.   
13 
 
 
Figure 7: Structures of TPP-12-IOA and TPP-12-ISA. 
 
Later, we were interested in studying the structure-activity relationship of molecules that have 
the imidazole moiety at different positions (6, 8, 10, 13 and 14) along the alkyl chain (Figure 8) 
on inhibiting the peroxidation activity of cytochrome c.   
 
 
Figure 8: General scheme for different positional imidazole derivatives.  
 
We designed and synthesized another group of molecules that are carnitine ester derivatives 
(Figure 9). Carnitine esters of fatty acids are part of the controlled mechanism of import of acyl 
chains into the mitochondria. We hypothesized that the attachment of carnitine esters may 
benefit the bio-compatibility and bio-availability of these compounds compared to the previously 
designed TPP derivatives. These molecules were tested for the ability to inhibit cyt c peroxidase 
activity in vitro. 
 
14 
 
 
Figure 9: Structures of the carnitine esters CSE-12-IOA and CSE-12-ISA.  
 
We designed and synthesized another set of compounds CDE-12-IOA and CDE-12-ISA 
(Figure 10). The double carnitine esters CDE-12-IOA and CDE-12-ISA are more hydrophobic 
and possess less detergent like properties than the single carnitine esters CSE-12-IOA and CSE-
12-ISA.  
 
 
Figure 10: Structures of carnitine double esters CDE-12-IOA and CDE-12-ISA 
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2. Results and Discussion 
 
2.1 Synthesis of positional isomers of imidazole substituted C18 fatty acids esters 
Our main goal was the synthesis of different fatty acid derivatives containing an imidazole group 
on the alkyl chain and esterified to a triphenylphosphonium salt to direct the compound to 
mitochondria. Our previous group members synthesized imidazole-substituted fatty acids and 
their esters. Those were imidazole substituted oleic acid (IOA), stearic acid (ISA), imidazole 
substituted methyl ester of oleic acid (IEOA) and imidazole substituted dodecanoic acid (IDA) 
(Figure 6). They hypothesized that these compounds interact with cytochrome c to position the 
imidazole group as a sixth ligand to the heme.
46
  
 
Molecular modelling and docking studies to partially unfolded cyt c showed that imidazole 
group of IOA, ISA and IEOA close to heme. The distances between heme-iron and imidazole 
nitrogen were 2.4 Å (IOA), 2.5 Å (IEOA) and 2.7 Å (ISA). The imidazole group of compound 
IDA was 6.9 Å away from the heme-iron atom.
46
 From the above data, it was confirmed that 
fatty acids with chains longer than C12 can lie in a hydrophobic groove of partially unfolded cyt 
c. The distance between the imidazole group and heme iron plays a major role in the activity.   
 
The Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) is used to detect hydrogen 
peroxide (H2O2) (and thus indirectly peroxidase activity) in picomolar concentration. The 
Amplex Red reagent, in combination with horseradish peroxidase (HRP) is used to detect H2O2 
released from biological samples, including cells, or generated in enzyme-coupled reactions. In 
the presence of HRP, the Amplex Red reagent reacts with H2O2 in a 1:1 stoichiometry to produce 
the red-fluorescent oxidation product, resorufin (Figure 11). Resorufin has absorption and 
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fluorescence emission maxima of approximately 571 nm and 585 nm, respectively. The assay for 
resorufin can be performed either fluorometrically or spectrophotometrically.  
 
Figure 11: Oxidation of Amplex Red to resorufin. 
Figure 12 shows the results of fluorescence Amplex Red based assay for the inhibitory activity 
of imidazole fatty acids and one ester against cyt c peroxidase. Here -TOCL is cyt c and H2O2 
lacking 1,1
′
,2,2
′ 
- tetraoleoyl cardiolipin (white bar) and + TOCL is cyt c and H2O2 plus 1,1
′
,2,2
′ 
- 
tetraoleoyl cardiolipin (black bar). The compounds IEOA, IOA, ISA and IDA were tested against 
 
Figure 12: Inhibition of peroxidase activity of cyt c/TOCL complexes with IEOA, IOA, ISA,                     
                  and IDA. 
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the peroxidase activity at different concentrations (0.5 to 5 µM). The inhibitory action on 
peroxidase activity increased upon increasing the concentrations of IEOA, IOA and, ISA 
compounds. On the contrary, the compound IDA was tested at 5 µM, but did not show any 
inhibition of the peroxidase activity of cyt c/cardiolipin complex. 
 
Curiously, despite the anticipated requirement of the free carboxylate for binding to cyt c, the 
methyl ester also showed inhibitory activity. The 12-imidazole-dodecanaote analogue was not 
active, illustrating that the full C18 carbon chain of the fatty acid is necessary for inhibitory 
activity. The binding mode of the 12-IOA and 12-ISA to partially unfolded human cyt c was 
modeled by Drs. Judith Klein-Seetharaman and Naveena Yanamala, (Dept. of Structural 
Biology, University of Pittsburgh) and are shown in Figure 13.     
 
Figure 13: Docked modeling for the binding of IOA to cytochrome c 
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Free imidazole substituted fatty acids and esters inhibit the apoptosis in cells and targeted into 
mitochondria. The internal charge of mitochondria is negative and the inner membrane potential 
is 150-180 mV.
50
 The large inner membrane potential should be used for delivering the 
molecules to mitochondria. Generally, the presence of the cationic charge on the delivering 
molecule favours the interaction with mitochondria. That is why lipophilic cations can pass 
easily through lipid bilayers. Here our group designed and synthesized imidazole fatty esters 
having the triphenylphosphonium group. The triphenylphosphonium group increases the cationic 
surface which can assist in interacting with mitochondrial membrane. These molecules enter into 
the cytoplasm from the extracellular environment driven by the plasma membrane potential (30-
60 mV) and again accumulated into mitochondria.
50,51
 Most of  TPP derivatives accumulated in 
mitochondria
46 
and inhibited apoptosis in cells, similarly to  IOA and ISA. Due to this reason, 
our group synthesized the TPP-12-IOA and TPP-12-ISA compounds.  
 
We synthesized different positional isomers of the imidazole ring on the long carbon chain, at 
positions 6, 8, 10, 13 and 14. Also prepared were C12 (saturated and unsaturated) imidazole 
carnitine monoesters as well as double esters. Compounds were sent to the Centre for Medical 
Countermeasures against Raditation (CMCR) at the University of Pittsburgh for biological 
testing.  In order to prepare these compounds we started with different hydroxy fatty acids, some 
of which are commercially available from natural sources and some which had to be prepared 
synthetically. Syntheses of all these compounds are shown in the corresponding schemes.   
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2.2.1 Synthesis of (S, Z)-(3-((12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)propyl)triphenyl-
phosphonium bromide  (TPP-12-IOA).   
TPP-12-IOA and TPP-12-ISA were synthesised from the commercially available starting 
material methyl ricinoleate. Both compounds were synthesized in similar manner (Scheme 1).  
Methyl ricinoleate 1 was mesylated by treating with methanesulfonyl chloride, in the presence of 
TEA and DMAP in DCM.
52
 The crude mesylated compound was heated with imidazole at 70
o
C 
to give the imidazole substituted compound 2 in 34% yield over the two steps.     
 
 
 
Reaction Conditions: (i) CH3SO2Cl, TEA, DMAP, DCM, 0
oC to RT; (ii) imidazole, 70oC, 16h, 34%; (iii) MeOH : 
H2O (3:1), NaOH, RT, 89%; (iv) Compound 5, DCC, DCM, 85%; (v) TPP, toluene, 110
oC, 16h, 95%. 
 
Scheme 1: Synthesis of TPP-12-IOA.  
 
We observed that most of the compound was the product of elimination because the secondary 
mesyl group is likely prone to this reaction. We used higher temperatures in the presence of 
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imidazole, and the pKa values of imidazole are 7 and 14.2
53
. Hydrolysis of the imidazole methyl 
ester 2 with NaOH in a mixture of methanol and water gave acid 3 in 89% yield.
54
 Compound 4 
was refluxed with TPP in toluene to produce the compound 5 in 95% yield.
55,56
 Compound 3 was 
esterified with (3-hydroxypropyl) triphenylphosphonium bromide 5 in the presence of DCC to 
give compound TPP-12-IOA in 85% yield.
57
     
 
2.2.2 Synthesis of (3-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-12-ISA)  
 
 
Reaction Conditions: (i) CH3SO2Cl, TEA, DMAP, DCM, 0
oC to RT.; (ii) imidazole, 70oC, 16h, 34%; (iii) MeOH : 
H2O (3:1), NaOH, RT, 89%; (iv) Compound 5, DCC, DCM, 85%.  
Scheme 2: Synthesis of TPP-12-ISA. 
 
Synthesis of TPP-12-ISA was started with 12-hydroxy stearic acid methyl ester and was 
prepared in an analogous fashion to TPP-12-IOA. The strategy for the synthesis of compound 
TPP-12-ISA was shown in the above Scheme 2.   
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2.2.3 Biological results of TPP-12-IOA and TPP-12-ISA  
TPP-12-IOA and TPP-12-ISA were both tested in in vitro and in vivo as inhibitors of cyt c 
peroxidase and as inhibitors of radiation induced apoptosis. Figure 14 shows the survival of 
mice that had been given doses of the compounds either before or directly after receiving a dose 
of radiation that is lethal to most of the animals by day 12 post-irradiation. For this experiment 
they used the three sets of mice that were observed over 60 days. 
 
 
Figure 14: Radiation protection and mitigation by TPP-12-IOA and TPP-12-ISA.
48
 
C57BL/6NTac female mice were exposed to total body irradiation to a dose of 9.25 Gy using (a) 
a cesium source (n = 31–35 mice per group) (b) a linear accelerator (n = 10–23 mice per group). 
The mice were irradiated and injected intraperitoneally (i.p.) with TPP-12-IOA or TPP-12-ISA 
(5 mg per kg body weight in 100 μl of water containing 25% ethanol) 10 min after irradiation. (i) 
The first set mice were exposed to total body irradiation at the dose of 9.25 Gy only (black 
circles). (ii) The second set mice were exposed to total body irradiation at the dose of 9.25 Gy 
and injected with TPP-12-ISA (5 mg per kg body weight) 10 min (blue triangles) (iii) The third 
set of mice were exposed to total body irradiation at the dose of 9.25 Gy and injected with TPP-
12-IOA (5 mg per kg body weight) 10 min (red squares).  
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Survival of the mice was monitored for 55 days. Most of the untreated mice (~75%) were dead 
after 15 days (black circles), and ~15% of mice survived from 25 to 55 days. Mice that were 
treated with TPP-12-IOA after radiation, showed 90% survival up to 15 days, and after that 
suddenly dropped to 70%, then after 25 days about 65% survived. In a third set of animals, ~90% 
of the mice that were treated with TPP-12-ISA were still alive at 10 days, 85% at 15 days and 
55% from day 25 onward. In the same way they tested again three more sets of mice with 
different conditions and their results are shown in the Figure 14b.  
 
The conditions are the same as in (a) but mice were injected with the compounds before and after 
irradiation. The mice were injected i.p. with TPP-12-IOA (5 mg per kg body weight in 100 μl of 
water containing 25% ethanol) at 1 h or 10 min before irradiation or 10 min, 5 or 24 h after 
irradiation. Mice were exposed to total body irradiation at the dose of 9.25 Gy only (black 
circles); to total body irradiation at the dose of 9.25 Gy and injected with TPP-12-IOA (5 mg per 
kg body weight) 10 min (blue circles), 5 h (blue triangles) and 24 h (blue squares) thereafter. 
Mice injected with TPP-12-IOA (5 mg per kg body weight) 10 min (red squares) and 1 h (red 
triangles) before total body irradiation (9.25 Gy).  
 
In the Figure 12 (b), those animals that received injections of TPP-12-IOA ten minutes after 
irradiation (blue circles) showed remarkable survival rates; 100% up to 40 days, then 95% up to 
55 days. 
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2.3.1 Synthesis of (3-((6-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-6-ISA)  
TPP-12-IOA and TPP-12-ISA were tested in vitro and in vivo and were shown to be active as 
inhibitors of cyt c peroxidase. It was not obvious from the preliminary assay and modeling 
results whether imidazole substitution at other places on the chain would decrease or increase 
inhibitory activity. We therefore planned to synthesize different positional isomers of imidazole 
on the alkyl chain, to study the structure activity relationship of TPP-imidazole fatty acids in an 
attempt to identify more potent compounds. TPP-12-ISA and TPP-12-IOA were made by using 
commercially available 12-hydroxy steric acid and ricinoleic acid. The 6, 8, 10, 13 and 14-
hydroxy fatty acids were synthesized by using different starting materials because these 
compounds are not commercially available. 6 and 8-Hydroxy fatty acids were synthesized from 
cycloalkenes. The 10-hyroxy fatty acid can also be prepared by using this method, but 
cyclodecene is more expensive. Because of this reason, 10-hydroxy fatty acid was prepared from 
1, 10-decanediol. The 13 and 14 hydroxy fatty acids were also synthesized from 1, 12-
dodecanediol.  
 
In general, ozonolysis of olefins gives the dialdehydes but conditions exist that produce a methyl 
ester and an aldehyde. Starting from a cyclic alkene would therefore provide a differentially 
terminally functionalized linear alkyl chain. Cleavage of cyclohexene 9 by passing ozone gas at  
-78
o
C through a suspension of compound 9 and NaHCO3 in DCM, followed by the addition of 
Ac2O and TEA for 15 minutes produced the aldehyde 10 in 63% yield.
58, 59
 Compound 10 in 
THF was added to dodecylmagnesium bromide at -20
o
C, which was prepared from 
1-bromododecane and magnesium metal in THF, to give the alcohol 11 in 47% yield. This 
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alcohol 11 was converted into the mesylate, and the mesyl group was displaced with imidazole to 
provide compound 12 in 34% yield. 
 
Reaction Conditions: (i) NaHCO3, ozone gas, -78
oC, DCM, TEA, Ac2O, DCM, 16h, 63%; (ii) 1-bromododecane , 
Mg, THF, -20oC, 3h, 47%; (iii) CH3SO2Cl, TEA, DMAP, DCM, 0
oC to RT, Imidazole, 70oC, 16h, 34%; (iv) MeOH 
: H2O (3:1), NaOH, RT, 3h, 77%; (iv) Compound 5, DCC, DCM, 16h , 67%.  
 
Scheme 3: Synthesis of TPP-6-ISA. 
 
 
Hydrolysis of compound 12 in the presence of a base gives carboxylic acid 13 in 77% yield.  The 
carboxylic acid 13 was coupled with phosphonium salt 5 to produce TPP-6-ISA in 67% yield. 
The last three steps were the same as those for the previous compounds TPP-12-IOA and TPP-
12-ISA (Scheme 1).    
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2.3.2 Synthesis of (3-((8-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-8-ISA) 
  
Reaction Conditions: (i) a) Cyclohexene, NaHCO3, ozone gas, -78
oC, DCM, TFA, Ac2O, DCM, 16h, 70%; (ii) 1-
bromododecane, Mg, THF, -20oC, 2h, 47%; (iii) CH3SO2Cl, TEA, DMAP, DCM, 0
oC to RT, Imidazole, 70oC, 16h, 
35%; (iv) MeOH : H2O (3:1), NaOH, RT, 83%; (v) Compound 5, DCC, DCM, 70%.  
 
Scheme 4: Synthesis of TPP-8-ISA. 
 
 
Compound TPP-8-ISA was synthesized by using the procedures of compound TPP-6-ISA but 
yields were little bit different from previous compound TPP-6-ISA. All the yields and conditions 
are shown in Scheme 4.  
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2.3.3 Biological results of compounds TPP-6-ISA and TPP-8-ISA 
Compounds TPP-6-ISA and TPP-8-ISA were tested and found to be competent inhibitors of cyt 
c peroxidase in in vitro. Based on these results we decided to study the structure activity 
relationship of different positional isomers of TPP-imidazole fatty acids to potentially identify 
more potent compounds. The aim is to create a robust structure-function study of these 
compounds to guide the choice of the best compound for further studies in mice. Compounds 
with the imidazole group substituted at C-6 or C-8 were synthesized and sent to our collaborators 
at the Centre for Medical Countermeasures against Radiation (CMCR) at the University of 
Pittsburgh.  
 
Figure 15: TPP-imidazole-stearic acid derivatives (TPP-ISAs) inhibit peroxidase activity of cyt 
c/TOCL complexes. New derivatives: TPP-6-ISA and TPP-8-ISA, and TPP-12-ISA. 
Conditions: buffer 20 mM HEPES (pH 7.4) with 100 µM DTPA, 1 µM cyt c 50, µM Amplex 
Red, 50 µM H2O2.  
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In Figure 15 blue and red colored bars indicate fluorescence intensity of cyt c and cyt c + TOCL 
respectively. The cyt c/TOCL complex showed the maximum peroxidase activity. The inhibitory 
studies were performed on 6-, 8- and 12-imidazole TPP stearates at various concentrations.  At 
lower and higher concentration (0.5 µM and 5 µM) for all three compounds, inhibitory action 
against peroxidase activity was found to be very similar. But at moderate concentration (1 µM 
and 2.5 µM) TPP-6-ISA and TPP-8-ISA appeared to be significantly better inhibitors compared 
to the TPP-12-ISA.  
 
2.4 Synthesis of (3-((10-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-10-ISA)  
The preparation of compound TPP-10-ISA is shown in Scheme 5. The 10-hydroxy fatty acid 
starting material is not commercially available. TPP-10-ISA can be synthesized by the 
ozonolysis of cyclodecene. But this starting material is very expensive. Due to this reason, the 
synthesis was started with decane-1,10-diol 19 which was treated with benzyl bromide and Ag2O 
in DCM at reflux for 16 h to give the mono protected compound 20 in 65% yield.
60
 Compound 
20 was oxidized with PCC in DCM
61
 to produce the aldehyde 21 in 78% yield. The bromooctane 
was first converted to a Grignard reagent with Mg metal and iodine in dry THF, and the solution 
so prepared was added to the aldehyde 21 in THF solution at 0
o
C to give the compound 22 in 
61% yield.  Mesylation of hydroxyl compound 22 was achieved with methanesulfonyl chloride, 
TEA and DMAP in DCM, which was substituted with imidazole by heating without solvent at 
70
o
C for 16h to give the compound 23 in 33% yield. Compound 23 was debenzylated with 10% 
palladium on carbon in ethanol under hydrogen gas balloon at reflux for two days to produce 
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hydroxyl compound 24 in 81% yield. Compound 24 was converted into acid 25
62
 with freshly 
prepared Jones reagent in acetone water mixture for 3 hours in 84% yield. The acid 25 was 
esterified with compound 5 by using DCC, DMAP in DCM to produce TPP-10-ISA in 77% 
yield.  
 
 
Reaction Conditions: (i) BnBr, Ag2O, DCM, reflux, 18h, 65%; (ii) PCC,DCM, 4h, 78%; (iii) Bromooctane, Mg, 
dry THF, 4h, 61%; (iv) a) CH3SO2Cl, TEA, DMAP, DCM, 2h; b)Imidazole, 16h, 70
oC, 32.5%; (v) 10% Pd-C, 
EtOH, reflux, 2 days, 81%; (vi) Jones reagent, Acetone, 3h, 84%; (vii) compound 5, DCC,DCM, 16h, 77%.   
 
Scheme 5: Synthesis of TPP-10-ISA 
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2.4.1 Synthesis of (3-((13-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-13-ISA) 
 
 
 
Reaction Conditions: (i) 48% HBr in H2O, Toluene and reflux, 3h, 78%; (ii) PCC, DCM, 4h, 72%; (iii) 1-
bromopentane, Mg, THF, 2h, 58%; (iv) NaCN, DMF, 16h, 92% (v) CH3SO2Cl, TEA, DMAP, DCM, 0
oC to RT,  2h, 
Imidazole, 70oC, 16h, 33%; (vi) NaOH, EtOH , H2O, reflux, 81%; (vii) Compound 5, DCC, DCM, 78%;  
 
Scheme 6: Synthesis of TPP-13-ISA 
 
 
Compound TPP-13-ISA (Scheme 6) was prepared from 1,12-dodecanediol 26 by mono 
bromination with 45% HBr in water and toluene at reflux for 3 hours to give compound 27
 
in 
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78% yield.
63
 Oxidation of alcohol 27 with PCC in DCM for 4h produced the aldehyde 28 in 72% 
yield. Pentyl magnesium bromide was prepared from bromopentane using magnesium metal in 
THF, which was added to compound 28 to give the alcohol 29 in 58% yield. The extension of 
one carbon on bromoalcohol 29 was achieved by the reaction between compound 29 and NaCN 
in DMF at 90
o
C to give compound 30 in 92% yield.
64
 Compound 30 was mesylated followed by 
imidazole substitution to give the compound 31 in 32% yield. Hydrolysis of compound 31 with 
NaOH in ethanol at reflux for 16h gave the acid 32 in 81% yield.
65
 Finally, the acid 32 was 
esterified with compound 5 using DCC and DMAP in DCM to produce the final compound 
TPP-13-ISA in 78% yield as a gummy liquid. 
 
 
2.4.2 Synthesis of (3-((14-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-14-ISA) 
Synthesis of TPP-14-ISA (Scheme 7) was started with compound 27 which was prepared in 
previous Scheme 6. Our goal was to extend the fatty acid chain by two carbon atoms on. It is 
possible by the substitution of bromo compound 27 with diethyl malonate. So the bromo 
compound 27 was treated with diethyl malonate in the presence of base and KI at reflux 
conditions to produce the compound 33 with extension of two carbon atoms in 63% yield.
66
 
Compound 33 was treated with PCC to produce the aldehyde 34 in 73% yield. The produced 
aldehyde 34 was treated with Grignard reagent to give the secondary alcohol 35 in 63% yield. 
Compound 35 was mesylated and substituted with imidazole at 70
o
C to produce the compound 
36 in 33 % yield.  
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Reaction Conditions: (i) Diethyl malonate, K2CO3, KI, Acetonitrile, 90
oC, 16h, 63%; (ii) PCC, DCM, 3h, 73%; 
(iii) 1-bromobutane, Mg, dry THF, 2h, 63%; (iv) CH3SO2Cl, TEA, DMAP, DCM, 0
oC to RT.; imidazole, 70oC, 16h, 
33%; (iii) MeOH : H2O (3:1), NaOH, RT, 170
0C, 15min, 68%; (iv) Compound 5, DCC, DCM, 71%. 
  
Scheme 7: Synthesis of TPP-14-ISA 
 
Hydrolysis followed by mono decarboxylation of diester 36  produced the mono acid 37 in 68 % 
yield.
66
 The mono acid 37 was esterified with compound 5 and DCC to obtain compound TPP-
14-ISA in 71% yield. 
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2.4.3 Biological results of compounds TPP-6-ISA, TPP-8-ISA, TPP-10-ISA, TPP-12-ISA, 
TPP-13-ISA and TPP-14-ISA
 
Figure 16: Effect of TPP- imidazole-stearic acid (TPP-ISA) derivatives on peroxidase activity of 
cyt c/TOCL complexes assessed by H2O2-dependent oxidation of Amplex Red. 
Conditions: cyt c (1 μM), H2O2 (50 μM), Amplex Red (50 μM). Experiments were performed in 
20 mM HEPES buffer (pH 7.4) containing DTPA (100 μM), cyt c was incubated with 
DOPC/TOCL liposomes ( 1:1) at ratio TOCL/cyt c 25:1. 
Insert: Effect of TPP-10-ISA on peroxidase activity of cyt c/TOCL complexes. 
 
 
In Figure 16 the grey and black colored bars represent fluorescence intensity of cyt c and cyt 
c/TOCL complex respectively. TPP imidazole stearic acids conjugates (6, 8, 10, 12, 13 and 14) 
were tested against the peroxidase activity in vitro by using Amplex Red as quantitative 
fluorescent indicator. The conjugates showed similar activity at higher concentrations (2.5 μM 
and 5 μM), but at lower concentrations (0.5 μM and 1 μM), TPP-6-ISA and TPP-8-ISA showed 
higher inhibitory action compared to other derivatives. The compound TPP-14-ISA at different 
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concentrations (0.5 μM to 5 μM) showed the lowest inhibition against peroxidase activity 
compared to other conjugates. 
 
2.5.1 Synthesis of Carnitine esters of IFAs 
Within the cell, import of fatty acids into mitochondria is strictly controlled. Free fatty acids are 
in very low concentration in most cells, occurring rather as esters with co-enzyme A or bound to 
binding and transfer proteins. 
67
  
 
Mainly three proteins are involved in this transport system carnitine palmitoyltransferase I (CPT-
I), carnitine acylcarnitine translocase (CACT) and carnitine palmitoyltransferase II (CPT-II).  
Each one of these proteins is located in different regions of mitochondria. Acyl-CoAs are 
synthesized by the catalytic action of long chain acyl-CoA synthetase (LCAS) in the 
mitochondrial outer membrane (MOM), then are transformed to acylcarnitines. CPT-I catalyzed 
this transesterification in the MOM. The formed long-chain acylcarnitines are transferred into the 
mitochondrial matrix by an exchange reaction catalyzed by CACT, an integral inner membrane 
protein. The acylcarnitines are then exchanged to the corresponding acyl-CoAs within the matrix 
by CPT-II, an enzyme associated with the inner leaflet of the mitochondrial inner membrane 
(MIM).
67
 
 
We synthesized carnitine esters of IFAs as these may also allow selective drug import into 
mitochondria by a more specific means than did the TPP conjugates. 
 
2.5.2 Synthesis of mono(2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-3-carboxy-
N,N,N-trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate) monochloride (CSE-12-
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IOA) and mono(2-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)-3-carboxy-N,N,N-
trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate) monochloride (CSE-12-ISA)   
 
 
Reaction Conditions: (i) Oxalyl chloride, DMF, DCM, (ii) Carnitine, TFA, 450C, 75% 
Scheme 8: Synthesis of CSE-12-IOA and CSE-12-ISA   
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Both carnitine esters CSE-12-IOA and CSE-12-ISA were prepared and purified by the same 
process. First, imidazole fatty acids 3 and 9 were converted into acid chlorides 38 and 40 with 
oxalyl chloride in DCM separately, and then these prepared acid chlorides were added to 
carnitine hydrochloride in TFA and heated at 50
o
C to produce the carnitine esters CSE-12-IFA 
and CSE-12-ISA in 75% yield.
68,69
 CSE-12-IFA and CSE-12-ISA were purified by 
precipitation method.  These pure compounds were obtained as TFA salts. We tried to convert 
TFA salts into HCl salts by using 6N HCl in dioxane. These TFA salts were dissolved in 1,4-
dioxane, then 6N HCl was added to it and concentrated under reduced pressure. This process was 
repeated for 3 times to get CSE-12-IFA and CSE-12-ISA as HCl salts. But, CSE-12-IFA and 
CSE-12-ISA were obtained as the 1:1 ratio of TFA and HCl salts. 
 
2.5.3 Biological results of CSE-12-IOA (12-CIOFA) and CSE-12-ISA (12-CISFA). 
 
 
 
Figure 17: Cytotoxicity of TPP or carnitine conjugated fatty acid in mouse embryonic cells. 
Cells were seeded in 24-well plate at a density of 0.02×10
6
/well and allowed to attach overnight. 
Cells were then incubated with fatty acid conjugates at the indicated concentration (1.25, 2.5, 5, 
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10 and 20 μM) for 48 hours. The cytotoxicity of fatty acid conjugates were assessed by annexin 
V/propidium iodide assay (flow cytometry) or Alarma blue assay (fluorescent 
spectrophotometry). (Data provide by the CMCR) 
 
Figure 17 shows that 12-CIOFA and 12-CISFA had very minimal detrimental effect at different 
concentrations on cell growth on non-treated cells, compared to 6- and 8-imidazole TPP 
derivatives which were shown to have concentration dependent growth inhibition of cells beyond 
a few micromolar concentration.  
 
 
 
 
 
 
 
 
Figure 18: Radiomitigative effect of TPP or carnitine conjugated fatty acid in mouse 
embryonic cells. Cells were seeded in 6-well plate at a density of 0.05×10
6
/well and allowed to 
attach overnight. Fatty acid conjugates were added to cells 15 min after gamma-irradiation 
exposure (10 Gy). Irradiation induced cell death was assessed by Annexin V/Propidium iodide 
staining assay using flow cytometry after 48 hours incubation. Data presented are the Annexin V 
positive cells. (Data provide by CMCR) 
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Figure 18 shows that 12-CIOFA and 12-CISFA did not exhibit radiomitigative effects at 
concentrations ranging from 1 - 5 μM, whereas the 6- and 8-imidazole TPP derivatives showed a 
concentration dependent (1 μM to 5 μM) increase in radiomitigative effects, as assessed by a 
decreasing degree of annexin V positive cells, a marker for apoptosis. 
 
 
 
Figure 19: Cytotoxicity of carnitine conjugated imidazole fatty acids (CISFA and CIOFA) 
in mouse embryonic cells. Cells were seeded in 24-well plate at a density of 0.015×10
6
/well and 
allowed to attach overnight. Cells were then incubated with fatty acid conjugates at the indicated 
concentration (50, 100, 200 and 400 μM) for 48 hours. The cytotoxicity of fatty acid conjugates 
were assessed by annexin V/propidium iodide assay (flow cytometry) or Alarma blue assay 
(fluorescent spectrophotometry). (Data provided by CMCR) 
 
Figure 19 shows that the cytotoxic effects of 12-CIOFA and 12-CISFA are concentration 
dependent beginning at ~100 µM. At 400 µM is the compounds are highly toxic to the cells. 
Compounds 12-CIOFA and 12-CISFA has also shown to reduce the cell growth at increasing 
concentrations. 
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Figure 20: Radiomitigative effects of carnitine conjugated imidazole fatty acids in mouse 
embryonic cells. Cells were seeded in 6-well plate at a density of 0.05×10
6
/well and allowed to 
attach overnight. Fatty acid conjugates (final, 50, 100, 200 and 400 μM) were added to cells 15 
min after gamma-irradiation exposure (10 Gy). Irradiation induced cell death was assessed by 
Annexin V/Propidium iodide staining assay using flow cytometry after 48 hours incubation. Data 
presented are the Annexin V positive cells. 
 
Figure 20 shows that the carnitine esters 12-CIOFA and 12-CISFA have mild radiomitigative 
effects up to 100 µM concentration. At concentrations of 12-CIOFA and 12-CISFA higher than 
100 µM, cytotoxic properties were shown to dominate.  
 
We inferred that the problem can be caused by either the detergent like properties of the 
compounds or cleavage of carnitine ester before inhibition. Detrimental effects of free fatty acids 
on mitochondria result in elevated levels of ROS via uncoupling of oxidative phosphorylation 
which further reduces the intracellular levels of glutathione by deterioration of endogenous 
antioxidant defence mechanism.  Incorporation of another methyl ester group on carnitine such 
as, methyl carnitine ester might render hydrophobic and detergent like properties which can 
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assist in easy absorption into the cells with low cytotoxicity. We hypothesis that the nonspecific 
esterases may cleave the 3-caboxy ester bond thereby releasing the fatty acid carnitine ester 
which is later absorbed into the mitochondrion where the carnitine ester is cleaved. Synthesis of 
double carnitine esters, such as CDE-12-IOA and CDE-12-ISA are shown Scheme 9.        
 
2.6 Synthesis of 2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-4-methoxy-N,N,N-
trimethyl-4-oxobutan-1-aminium iodide (CDE-12-IOA)  and 2-((12-(1H-imidazol-1-
yl)octadecanoyl)oxy)-4-methoxy-N,N,N-trimethyl-4-oxobutan-1-aminium iodide (CDE-12-
ISA) 
 
Reaction Conditions: (i) Carnitine hydrochloride, 57% HI in water, methanol, reflux, 6h, 60%, 
(ii) compound 3 or 9, compound 41, DCC, DMAP, THF and DCM, 16h. 
 
Scheme 9: Synthesis of CDE-12-IOA and CDE-12-ISA. 
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Carnitine methyl ester 41 was prepared by refluxing carnitine hydrochloride 39 in methanol and 
hydroiodic acid for 16 h.
71
 The carnitine methyl ester 41 was esterified with compounds 3 and 9 
to give the compound CDE-12-IOA and CDE-12-ISA respectively (Scheme 9).
72
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3. Conclusion and Future Work 
 
We synthesized six positional isomers of imidazole substituted fatty acids (6, 8, 10, 12, 13, and 
14 stearates, plus 12-imidazole substituted oleate) as the TPP ester derivatives. We also prepared 
the 12-imidazole carnitine single esters and double esters as the saturated and unsaturated fatty 
acid derivatives. TPP-12-IFA and TPP-12-ISA derivatives were tested in in vitro and in vivo, and 
showed dose dependent inhibition of cyt c peroxidase activity. The TPP imidazole fatty acid 
derivatives and the single carnitine esters were tested only in vitro. Of all these tested 
compounds, compound TPP-8-ISA has more inhibitory activity in vitro against the cyt c 
peroxidase activity compared to the other compounds. Single carnitine esteres showed low 
inhibiter activity against the peroxidase activity.  We are hoping to receive biological data on the 
double carnitine esters in the near future. After getting those results we will confirm whether it is 
worth pursuing the carnitine double esters.  
 
TPP-8-ISA was tested as a racemic mixture in vitro against the cyt c peroxidase activity.  Both 
isomers of the TPP-8-ISA will be synthesized separately and will be tested against the cyt c 
peroxidase activity in order to affirm which isomer shows high inhibition. 8-hydroxy fatty acid 
will be used as a starting material to synthesize the two isomers of TPP-8-ISA. In the beginning, 
secondary alcohol will be oxidised to a ketone followed by converting it back to an alcohol in the 
presence of chiral catalyst to obtain a single isomer of an 8-hydroxy fatty acid. This single 
isomer (R or S) of the alcohol will then be converted into another isomer (S or R) by using 
Mitsunobu reaction. These two alcohols will then be transformed into two single isomers (R and 
S) of TPP-8-ISA.  
 
42 
 
4. Experimental 
General 
All reagents were purchased from Sigma – Aldrich Co., Oakville, Ontario. All glassware was 
dried in an oven at 90
o
C overnight, and then cooled in desiccators before use. Cooling baths were 
prepared with dry ice in ethyl acetate for -78
o
C and ice/salt mixture for 0
o
C – 15oC. All air and 
moisture sensitive reactions were performed under nitrogen gas. THF and Et2O were distilled 
with sodium/benzophenone before use. DCM was dried over CaH2. Methanol was distilled from 
Mg/iodine. Reagent grade solvents were used for extraction and column purifications. Distilled 
water was used for all aqueous workups. 
 
Analytical thin layer chromatography (TLC) was done on Merck 0.25 mm pre-coated silica gel  
60 A
o 
 F-254 on aluminum sheets and visualized under UV light or stained with iodine in silica 
gel,  KMnO4 solution, ninhydrin solution or vanilin solution. Column chromatography was 
performed on silica gel 230 – 400 mesh purchased from SiliCycle Inc, Quebec, Canada. 
1
H NMR and 
13
C NMR spectra were measured on a Bruker Advance DPX – 300 digital FT – 
NMR spectrometer (300 and 75 MHz respectively) and Bruker 600 NMR spectrometer (600 and 
151 MHz respectively) in CDCl3 with residual chloroform as internal reference (7.281 ppm for 
1
H and 77.0 for 
13
C) unless otherwise mentioned. Chemical shifts were reported as δ values and 
coupling constants (J) were reported in Hertz (Hz). The following abbreviations were used as s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Mass spectra (MS) 
were recorded on Carlo Erba/Kratos GC/MS Concept 1S double focusing mass spectrometer 
interfaced to a Kratos DART acquisition system and a Sun SPARC workstation. Samples were 
introduced through a direct inlet system. Ions were generated by using electron impact (EI) or 
Fast Atom Bombardment (FAB) and were reported as m/z values.  
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Synthesis of (R,Z)-methyl 12-(1H-imidazol-1-yl)octadec-9-enoate (2) 
 
 
 
Methyl ricinoleate (1) (10.0 g, 32 mmol), TEA (5.8 ml, 41.60 mmol) and DMAP (0.39 g, 3.2 
mmol) were dissolved in dry DCM (150 ml), cooled to 0
0
C, then methanesulfonyl chloride (2.72 
ml, 33.60 mmol) was added slowly under nitrogen gas, stirred at room for another 2 h. The 
reaction mixture was diluted with DCM, washed with water, brine solution, dried over anhydrous 
MgSO4 and then concentrated. This crude compound was heated with imidazole without solvent 
at 70
o
C for 16 h under a nitrogen atmosphere. The crude product was purified by silica gel 
column chromatography (2% MeOH in DCM) and provided compound 2 (3.95 g, 34%) as a 
gummy liquid.  
 
TLC  Rf = 0.45 (5% MeOH in DCM, KMnO4 and iodine active.) 
1
H NMR (300 MHz, CDCl3) δ:7.46 (s, 1H), 7.07 (s, 1H), 6.91 (s, 1H), 5.46 – 5.40 (m, 1H), 
5.20 - 5.17 (m, 1H), 3.95 - 3.90 (m, 1H), 3.68 (s, 3H), 2.51 – 2.42 (m,  2H), 
2.31(t, J  = 7.5 Hz, 2H), 1.93 – 1.91 (m, 2H), 1.82 – 1.72 (m, 3H), 1.65 – 1.58 (m, 
2H), 1.28 – 1.56 (m, 16H), 0.90 – 0.84 (m, 3H).     
13
C NMR   (151 MHz, CDCl3) δ: 174.28, 135.46, 134.97, 122.35, 121.17, 118.67, 61.80, 
54.80, 51.44, 34.62, 34.00, 33.40, 31.43, 29.20, 29.03, 28.96, 28.72, 27.28, 25.81, 
24.84, 22.45, 13.96.  
MS (EI)  m/z: [M+] 362 (6.9%), 165 (100%), 69 (21%), 55 (16.8%).  
HRMS  Calculated: 362.5493   Found: 362.2926 
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Synthesis of (S, Z)-12-(1H-imidazol-1-yl)octadec-9-enoic acid (3)  
 
 
 
To a stirred solution of compound 2 (2.50 g, 6.9 mmol) in a mixture of MeOH (30 ml) and water 
(10 ml), was added NaOH (0.83 g, 20.67 mmol) at 0
o
C, which was then allowed to warm to 
room temperature and stirring was continued for another 3 h. The reaction mixture was 
concentrated to remove methanol, then the aqueous layer was acidified with 1N HCl to pH 4, and 
extracted with DCM (3x50 ml). The combined organic layers were washed with brine solution, 
dried over anhydrous MgSO4 and then concentrated. The crude product was purified by silica gel 
column chromatography (5% MeOH in DCM) to obtain compound 3 (2.16 g, 89%) as a pale 
yellow gummy liquid.   
 
TLC  Rf = 0.54 (10% MeOH in DCM, iodine and KMnO4 active.) 
1
H NMR (300 MHz, CDCl3) δ: 10.06 (b, 2H), 9.19(s, 1H), 7.47(s, 1H), 7.21(s, 1H), 5.52 – 
5.40 (m, 1H), 5.24 - 5.16 (m, 1H), 4.45 – 4.35(m, 1H), 2.60 – 2.53(m, 2H), 2.34 – 
2.29 (m, 2H), 1.87 (m, 4H), 1.61 – 1.54 (m, 2H), 1.26 – 1.11 (b, 17H), 0.86 – 0.82 
(m, 3H).   
13
C NMR   (75 MHz, CDCl3) δ: 177.41, 135.15, 134.58, 122.25, 120.43, 118.62, 61.80, 
34.66, 34.02, 33.42, 31.41, 28.88, 28.66, 28.62, 27.09, 25.80, 24.59, 22.44, 13.96. 
MS (EI)  m/z: 149 (4.8%), 101 (18.6%), 59 (52.5%), 58 (22.9%), 43 (100%).  
HRMS  Calculated: 348.5227   Found: 348.2784 
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Synthesis of (3-hydroxypropyl)triphenylphosphonium bromide (5) 
 
 
 
3-Bromo-1-propanol 4 (5.0 g, 35.97 mmol) and triphenylphosphine (10.38 g, 39.57 mmol) were 
dissolved in toluene (100 ml) and heated at 110
o
C for 16 h. After cooling to room temperature, 
the reaction mixture was concentrated under reduced pressure. The crude compound was washed 
with 1:4 of DCM:hexane to remove unreacted compound 4 and triphenylphosphine. Compound 
5 was so obtained as an off – white solid (13.06 g, 95%). 
 
TLC  Rf = 0.25 (10% MeOH in DCM, iodine and KMnO4 active.) 
1
H NMR (600 MHz, CDCl3) δ: 7.80 – 7.75 (m, 9H), 7.71 – 7.68 (m, 6H), 3.82 (m, 2H), 
3.76 – 3.72 (m, 2H), 3.25 (br, 1H), 1.87 – 1.81 (m, 2H).   
13
C NMR   (151 MHz, CDCl3) δ: 135.12, 133.55, 133.48, 130.62, 130.54, 118.64, 118.06, 
60.40, 60.29, 25.84, 20.32, 19.98.  
MS (EI)  m/z: 149 (4.8%), 101 (18.6%), 59 (52.5%), 58 (22.9%), 43 (100%).  
HRMS  Calculated: 348.5227   Found: 348.2784 
 
Synthesis of (S,Z)-(3-((12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)propyl)triphenyl-
phosphonium bromide (TPP-12-IOA) 
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Compound 3 (0.54 g, 1.55 mmol) and compound 5 (0.622 g, 1.55 mmol) were dissolved in DCM 
(10 ml), cooled to 0
o
C, to which was then added DCC (0.32g, 1.55mmol) under nitrogen 
atmosphere. The reaction solution was stirred overnight at room temperature, and the 
precipitated DCU removed by filtration. The filtrate was concentrated by evaporation. The crude 
product was purified by silica gel column chromatography (4% MeOH in DCM) to give title 
compound TPP-12-IOA (0.96mg, 85%) as gummy liquid. 
 
TLC  Rf = 0.45 (10% MeOH in DCM, KMnO4 and iodine active). 
1
H NMR (600 MHz, CDCl3) δ: 7.85 – 7.77 (m, 9H), 7.70 – 7.67 (m, 6H), 7.44 (s, 1H), 7.01 
(s, 1H), 6.86 (s, 1H), 5.37 (m, 1H), 5.37 (m, 1H), 4.34 (t, J = 6 Hz, 2H), 3.95 – 
3.91 (m, 3H), 2.4 (bs, 1H), 2.23 – 2.20 (m, 2H), 1.99 – 1.98 (m, 2H), 1.85 – 1.84 
(m, 2H), 1.52 – 1.49 (m, 2H), 1.25 – 1.15 (m, 16H), 0.82 – 0.80 (m, 3H).  
13
C NMR   (151 MHz, CDCl3) δ : 173.41, 135.19, 133.72, 133.65, 133.40, 130.61, 130.53, 
123.97, 118.24, 117.67, 63.14, 63.02, 58.74, 35.44, 34.23, 34.09, 31.54, 29.30, 
29.10, 29.01, 28.81, 27.21, 25.98, 24.76, 22.48, 22.25, 19.91,19.56, 14.01.   
MS (EI) m/z: [M+1] 652.5 (46.5%), 651.5 (100%), 326.8 (11.4%), 326.3 (27.8%). 
 
Synthesis of methyl 12-(1H-imidazol-1-yl)octadecanoate (7) 
 
 
 
Compound 6 (2.0 g, 6.36 mmol), TEA (1.15 ml, 8.27 mmol) DMAP (78 mg, 0.64 mmol) were 
dissolved in DCM (30 ml) under nitrogen atmosphere, cooled 0
o
C, then  methanesulfonyl 
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chloride (0.54 ml, 6.68 mmol) was added drop wise for 10 minutes. The reaction was stirred at  
room temperature for another 2 h. The reaction was diluted with DCM (40 ml), washed with 
water (40 ml), 1N HCl (20 ml), brine solution and dried over anhydrous MgSO4 and 
concentrated.  The crude mesylated compound and imidazole (0.87 g, 12.73 mmol) mixture was 
heated at 70
o
C for 16 hours. The crude compound was purified by using silica gel column (2% 
MeOH in DCM) to give compound 8 as light yellow liquid (0.81 g, 35%). 
 
TLC  Rf = 0.55 (5% MeOH in DCM, KMnO4 and iodine active).  
1
H NMR (300 MHz, CDCl3) δ: 7.35 (s, 1H), 6.95 (s, 1H), 6.78 (s, 1H), 3.78 (m, 1H), 3.54 
(s, 3H), 2.18 (t, J = 7.5 Hz, 2H), 1.61 – 1.47 (m, 6H), 1.15 – 0.94 (m, 22H), 0.76 – 
0.71 (m, 3H).  
13
C NMR   (75 MHz, CDCl3) δ: 174.04, 136.36, 129.26, 116.25, 58.53, 51.23, 36.43, 36.20, 
34.56, 34.05, 33.92, 31.63, 31.46, 29.26, 29.21, 29.06, 28.97, 28.74, 25.93, 25.90, 
25.16, 24.79, 22.38.  
MS (EI) m/z: [M
+
] 364 (29.5%), 363 (29.2%), 223 (63.8%), 221 (100%), 171 (32.6%), 95 
(30.6%), 82 (33.7%), 69 (77.8%), 55 (50.6%) 
HRMS  Calculated: 364.5652   Found: 364.3085. 
 
Synthesis of 12-(1H-imidazol-1-yl)octadecanoic acid (8) 
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NaOH (263 mg, 6.58 mmol) was added to a stirred solution of compound 7 (800 mg, 2.19 mmol) 
in methanol (9 ml) and water (3 ml) mixture at 0
o
C. Reaction was stirred at room temperature for 
2h, then the reaction mixture was concentrated to remove methanol. Aqueous layer was acidified 
with 1N HCl up to pH 4, extracted with DCM (3x40 ml), combined organic layers were washed 
with brine solution, dried over MgSO4 and concentrated.  Compound was purified by silica gel 
column (4% MeOH in DCM) to give compound 8 as gummy liquid (682 mg, 89%) 
 
TLC  Rf = 0.52 (10% MeOH in DCM, KMnO4 and iodine active). 
1
H NMR (300 MHz, CDCl3) δ: 10.899 (s, 2H), 8.68 (s, 1H), 7.33 (s, 1H), 7.05 (s, 1H), 4.17 
(m, 1H), 2.29 (t, J = 7.5 Hz, 2H), 1.83 – 1.54 (m, 6H), 1.52 – 1.19 (m, 20H), 1.03 
– 1.02 (br, 2H), 0.84 – 0.80 (m, 3H). 
13
C NMR   (75 MHz, CDCl3) δ: 177.76, 135.19, 123.11, 117.62, 61.04, 35.76, 35.70, 34.46, 
31.44, 29.07, 29.01, 28.91, 28.71, 25.81, 25.71, 24.87, 22.44, 13.94. 
MS (EI) m/z: [M
+
] 350 (2%), 265 (45.5%), 165 (78.7%), 95 (19.2%), 69 (100%), 55 
(38.8%), 43 (37.7%), 41 (33%). 
HRMS  Calculated: 350.5386   Found: 350.2918. 
 
Synthesis of (3-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-12-ISA) 
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DCC (359 mg, 1.74 mmol) was added to a stirred solution of compound 8 (610 mg, 1.74 mmol) 
and compound 5 (698 mg, 1.74 mmol) in DCM (10 ml) at 0
o
C under N2 gas. The reaction 
mixture was stirred at room temperature for 16 h. The reaction mixture was filtered, and 
concentrated. The crude compound was purified by silica gel column (5% MeOH in DCM) to 
give compound TPP-12-ISA (1.05 g, 82%) as gummy liquid. 
 
TLC  Rf = 0.35 (10% MeOH in DCM, KMnO4 active). 
1
H NMR (300 MHz, CDCl3) δ: 7.80 – 7.67 (m, 15H), 7.50 (s, 1H), 7.08 (s, 1H), 6.90 (s, 
1H), 4.39 (t, J  = 6.3 Hz,2H), 4.12 – 4.02 (m, 2H), 3.93 – 3.85 (m, 1H), 2.24 (t, J 
= 7.5 Hz, 2H), 2.08 – 1.95 (m, 2H), 1.78 – 1.67 (m, 4H), 1.56 – 1.51 (m, 2H), 
1.26 - 1.06 (m, 23H), 0.87 – 0.83 (m, 3H).       
13C NMR  (CDCl3) δ 173.1, 134.9, 134.9, 133.4, 133.3, 130.4, 130.2, 118.2, 117.0, 116.2, 
62.9, 62.6, 58.4, 36.0, 33.8, 31.2, 29.0, 28.8, 28.7, 28.5, 25.7, 25.6, 24.5, 22.2, 
21.9, 19.8, 19.1, 13.7. 
MS (FAB)  m/z: [M
+
] 653 (100%), 375 (9%), 319 (12%), 275 (12%), 262 (14%), 183 (12%), 
69 (55%). 
 
Synthesis of methyl 6-oxohexanoate (10) 
 
 
 
Cyclohexene 9 (6.16 g, 75.02 mmol) and NaHCO3 (2.0 g, 24.01 mmol) were suspended in 250 
ml of DCM, cooled to -78
o
C, then ozone gas was bubbled through the solution until a light blue 
color appear. The ozone outlet was removed from the reaction and nitrogen gas bubbled through 
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the solution to remove excess ozone, then the solution was allowed to room temperature and 
filtered off the NaHCO3, then 80 ml of benzene was added to the mixture and the volume reduced 
to 50 ml. The solution was diluted with another 225 ml of dichloromethane, then triethylamine 
(22 ml, 112.5 mmol) and acetic anhydride (19.63 ml, 225.1 mmol) were added at 0
o
C. The 
mixture was warmed to room temperature and stirring continued overnight. The mixture was 
diluted with 100 ml of DCM, washed with 150 ml of 0.1N HCl, 150 ml of 10% NaOH solution, 
brine solution, dried on anhydrous MgSO4, and concentrated. The crude compound was distilled 
at 60
0
C under 0.1 mm vacuum to obtain compound 10 as colorless liquid (6.8 g, 63%).  
 
TLC  Rf = 0.5 (20% ethyl acetate in hexanes, iodine and KMnO4 stain).  
1
H NMR (300 MHz, CDCl3) δ: 9.76 (t, J = 1.8 Hz, 1H), 3.66 (s, 3H), 2.48 – 2.43 (m, 2H), 
2.36 – 2.31 (m, 2H), 1.69 – 1.66 (m, 4H).  
13
C NMR (151 MHz, CDCl3) δ: 201.85, 173.43, 51.28, 43.26, 33.48, 24.17, 21.32. 
MS (EI) m/z: 145 [M+1]
+
 (3.0%), 129 (28.3%), 114 (45.9%), 113 (25.4%), 101 (51.5%),  
100 (26.6%), 87 (53.4%), 74 (79.9%), 59 (100%), 55 (88.4%), 43 (82.4%), 41 
(49.8%). 
 
Synthesis of methyl 6-hydroxyoctadecanoate (11) 
 
 
 
Magnesium metal (0.359 g, 14.56 mmol) was added into dry THF (10 ml) in a 100 ml two-
necked round bottom flask which was equipped with condenser and nitrogen gas inlet.  The 
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flask was heated to 70
o
C, then four to five drops of 1, 2-dibromoethane was added to the 
reaction mixture, followed by slow addition of 1-bromododecane (2.92 g, 11.726 mmol) at 
reflux and stirring continued another 30 min. The Grignard reagent was added drop wise to a 
stirred solution of methyl 6-oxohexanoate (1.31 g, 11.49 mmol) in THF (15 ml) at -20
o
C. The 
reaction mixture was slowly brought to room temperature, and stirring continued for another 2h. 
The mixture was quenched with saturated ammonium chloride solution, extracted with 
(3x40ml) of ethyl acetate and the combined organic layers were washed with brine solution, 
dried on anhydrous MgSO4, concentrated. The crude compound was purified by silica gel 
column chromatography (2:8 ethyl acetate and hexanes) to offer compound 11 as a white 
coloured low melting solid (1.55 g, 47%).  
 
TLC   Rf = 0.42 (20% ethyl acetate in hexanes, iodine and KMnO4 active).  
1
H NMR  (300 MHz, CDCl3) δ: 3.68 (s, 3H), 3.60 (m, 1H), 2.34 (t, J = 7.5 Hz, 2H), 1.70 – 
1.61 (m, 2H), 1.52 – 1.27 (m, 26H), 0.91 – 0.87 (m, 3H).   
13
C NMR  (75 MHz, CDCl3) δ: 174.16, 71.55, 51.42, 37.49, 36.95, 33.97, 31.88, 29.67, 
29.61, 29.31, 25.63, 25.17, 24.87, 22.64, 14.06.  
MS (EI)  m/z: 264 (4.8%), 158 (9.5%) 145 (20.8%), 113 (38.4%), 87 (49%), 67 (41.8%), 
55 (99.5%), 41 (100%). 
HRMS  Calculated: 314.5032   Found: 296.2717 – H2O 
 
 
 
 
52 
 
Synthesis of methyl 6-(1H-imidazol-1-yl)octadecanoate (12) 
 
 
 
Methanesulfonyl chloride (0.39 ml, 4.99 mmol) was added drop wise to a stirred solution of 
compound 11 (1.55 g, 4.94 mmol) and TEA (0.89 ml, 6.42 mmol) in dry DCM (30 ml) at 0
o
C. 
The reaction mixture was warmed to room temperature and stirring continued for 2h. The 
reaction mixture diluted with 50 ml of DCM, the organic layer was washed with water and brine 
solution, dried on anhydrous MgSO4, concentrated. This crude compound was combined with 
imidazole (0.67 g, 9.88 mmol) heated at 80
o
C for 16 h. The crude compound was purified by 
silica gel column (2% methanol in DCM) to obtain compound 12 as light brown liquid (605 mg 
33.7%).  
 
TLC  Rf = 0.45 (5% methanol in dichloromethane, iodine and KMnO4 active).  
1
H NMR  (300 MHz, CDCl3) δ: 7.46 (s, 1H), 7.07 (s, 1H), 6.87 (s, 1H), 3.88 (m, 1H), 3.63 
(s, 3H), 2.24 (t, J = 7.5 Hz, 2H), 1.71 - 1.48 (m, 6H), 1.23 - 1.09 (m, 22H), 0.88 – 
0.84 (m, 3H). 
13
C NMR  (75 MHz, CDCl3) δ: 173.75, 58.47, 51.48, 36.27, 35.98, 33.67, 31.87, 29.58, 
29.55, 29.47, 29.36, 29.30, 29.16, 26.02, 25.56, 24.40, 22.65, 14.08.  
MS (EI)  m/z: 364 (8.6%), 363 (10.7%), 249 (32.2%), 95 (24.3%), 82 (15.3%), 81(16.0%) 
69 (100%), 57 (20.2%) 55(41.7%), 43 (81.9%). 
HRMS  Calculated: 364.5652   Found: 364.3092. 
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Synthesis of 6-(1H-imidazol-1-yl)octadecanoic acid (13) 
 
 
 
Sodium hydroxide (0.11 g, 2.75 mmol) was added to a stirred solution of compound 12 (0.5 g, 
1.37 mmol) in a mixture of methanol (9 ml) and water (3 ml) at 0
o
C, and stirring continued for 
another 3 hours at room temperature. The reaction mixture was concentrated to remove the 
methanol. The aqueous layer was diluted with water and acidified with 1N HCl up to pH 4, 
extracted with dichloromethane (3 x 15 ml), and the combined organic layers were washed with 
brine solution, dried on anhydrous MgSO4, and concentrated. The crude product was purified on 
silica gel column (5% MeOH in DCM) to obtain compound 13 as gummy liquid (370 mg, 
77%). 
 
TLC   Rf = 0.52 (10% MeOH in DCM, KMnO4 and iodine active). 
1
H NMR  (300 MHz, CDCl3) δ: 12.95 (s, 1H), 7.80 (s, 1H), 7.13 (s, 1H), 6.92 (s, 1H), 4.00 
– 3.98 (m, 1H), 2.37 – 2.20 (m, 2H), 1.80 - 1.51 (m, 6H) 1.30 – 1.08 (m, 22H), 
0.90 – 0.86 (m, 3H).  
13
C NMR  (75 MHz, CDCl3) δ: 176.98, 135.96, 126.87, 116.68, 59.27, 36.17, 35.79, 34.47, 
31.89, 29.61, 29.56, 29.49, 29.35, 29.32, 29.16, 26.03, 25.35, 24.48, 22.67, 
14.10.  
MS (EI)  m/z: 351 (2.5%), 350 (10.5%), 349 (10.2%), 249 (46.3%), 181 (14.2%), 95 
(23.3%), 69 (100%), 55 (38%), 43 (58%), 41(63%). 
HRMS   Calculated: 350.5386   Found: 350.2935. 
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Synthesis of (3-((6-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-6-ISA) 
 
 
 
Compound 13 (300 mg, 0.857 mmol) and compound 5 (344 mg, 0.858 mmol) were dissolved in 
dry DCM (10 ml), then DCC (177 mg, 0.858 mmol) was added at 0
o
C. The reaction mixture was 
stirred for 16h at room temperature. The mixture was filtered and concentrated, purified by silica 
gel column chromatography (6% MeOH in DCM) to obtain compound TPP-6-ISA as gummy 
liquid (420 mg, 67%).  
 
TLC  Rf = 0.43 (15% MeOH in DCM, iodine and KMnO4 active).  
1
H NMR  (600 MHz, CDCl3) δ: 7.74 - 7.60 (m, 15H), 7.38 (s, 1H), 6.89 (s, 1H), 6.80 (s, 
1H), 4.20 (s, 2H), 3.80 – 3.79 (m, 3H), 2.11 – 2.07 (m, 2H), 1.87 – 1.86 (m, 2H), 
1.59 – 1.58 (m, 4H), 1.46 - 1.35 (m, 2H), 1.11 – 0.93 (m, 24H), 0.74 – 0.72  (m, 
3H).  
13
C NMR  (151 MHz, CDCl3) δ: 172.84, 136.29, 135.16, 135.15, 133.62, 133.56, 130.57, 
130.48, 128.96, 118.06, 117.49, 116.50, 63.15, 63.03, 58.47, 36.16, 35.85, 33.68, 
31.77, 29.48, 29.45, 29.38, 29.28, 29.19, 29.08, 25.93, 25.42, 24.17, 22.55, 22.10, 
19.89, 19.54, 14.03.  
MS (FAB)  m/z: [M+1]
+
 654 (46.9%), [M]
+
 653 (100%), 319 (12.1%), 303(10.5%),  275 
(11%), 262 (12.7%), 183(11.5%), 69 (30.8%). 
HRMS  Calculated: 653.8953   Found: 653.4220. 
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Synthesis of methyl 8-oxooctanoate (15) 
 
 
 
Cis-cyclooctene 14 (10.0 g, 90.74 mmol) and NaHCO3 (2.44 g, 29.05 mmol) were suspended in 
DCM (400 ml), and then ozone gas was bubbled through the solution at -78
o
C until a light blue 
color appeare. The ozone outlet was removed from the mixture and nitrogen gas bubbled 
through the solution to remove excess ozone. It was allowed to warm to room temperature and 
filtered. 100 ml of benzene was added to the mixture and the volume reduced by evaporation to 
100 ml. The solution was diluted with another 400 ml of DCM, and then triethylamine (18.94 
ml, 136.1 mmol) and acetic anhydride (25.7 ml, 272.2 mmol) were added to it at 0
o
C and 
stirring continued overnight at room temperature. Mixture was diluted with 200 ml of DCM, 
washed with 200 ml of 0.1N HCl, 200 ml of 10% NaOH solution, brine solution, dried on 
anhydrous MgSO4, and concentrated. The crude compound was distilled at 96
o
C under 0.1 mm 
vacuum to obtain compound 15 as colorless liquid (10.9g, 70%).  
 
TLC  Rf = 0.45 (20% Ethyl acetate in hexanes, iodine and KMnO4 stain).  
1
H NMR  (300 MHz, CDCl3) δ: 9.52 (t, J = 1.8 Hz, 1H), 3.42 – 3.40 (m, 3H), 2.21 - 2.17 
(m, 2H), 2.08 - 2.03 (m, 2H), 1.40 – 1.39 (m, 4H), 1.12 – 1.11(m, 4H).  
13
C NMR (75 MHz, CDCl3) δ: 202.04, 173.56, 51.00, 43.41, 33.53, 28.54, 28.48, 24.40, 
21.55.  
MS (EI)  m/z: 173 [M+1] (2.4%), 171 (5.4%), 157 (24.35%), 138 (49.7%), 129 (24.6%), 
97 (32.9%), 87 (37.3%), 74 (100%), 69 (50.7%). 
HRMS  Calculated: 172.2215   Found: 171.1019. 
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Synthesis of methyl 8-hydroxyoctadecanoate (16) 
 
 
 
Magnesium metal (0.209 g, 8.71 mmol) was added in dry THF (10 ml) in a 50 ml two-necked 
round bottom flask fitted with a condenser and nitrogen gas inlet. 1-Bromodecane (1.3 g, 5.81 
mmol) was added slowly at reflux temperature after initiating the reaction with 1,2-dibromo 
ethane and stirring continued for 30 min. The cooled Grignard reagent was added drop wise to a 
stirred solution of compound 15 (1.0 g, 5.8 mmol) in THF (10 ml) at -20
o
C, and the reaction 
mixture was slowly warmed to room temperature and stirring continued for 2h. The reaction 
mixture was quenched with saturated ammonium chloride solution, extracted with (3 x 25 ml) 
ethyl acetate, and the combined organic layers were washed with brine solution, dried on 
anhydrous MgSO4, concentrated. The crude was purified on silica gel column chromatography 
(20% EtOAc and hexanes) to obtain compound 16 as off-white solid (450 mg, 47%).  
 
TLC  Rf = 0.4 (20% ethyl acetate in hexanes, iodine and KMnO4 stain).  
1
H NMR  (300 MHz, CDCl3) δ: 3.66 (s, 3H), 3.57 (m, 1H), 2.30 (t, J = 7.5 Hz, 2H), 2.17 
(s, 1H), 1.62 – 1.58 (m, 4H), 1.42 - 1.25 (m, 26H), 0.89 - 0.85 (m, 3H).  
13
C NMR  (75 MHz, CDCl3) δ 174.28, 71.94, 51.44, 37.49, 37.35, 34.05, 31.89, 29.70, 
29.61, 29.32, 29.29, 29.09, 25.64, 25.43, 24.86, 22.67, 14.10. 
MS (EI)  m/z: 296 [M-18]
+
 (0.5%), 173 (43.4%), 144 (53.3%), 141 (100%). 
HRMS  Calculated: 314.5032   Found: 296.2718 (– H2O). 
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Synthesis of methyl 8-(1H-imidazol-1-yl)octadecanoate (17) 
 
 
 
To a stirred solution of compound 16 (0.92 g, 2.93 mmol) DMAP (30 mg) and TEA (0.42 ml, 
6.42 mmol) in dry DCM (30 ml) at 0
o
C, then methanesulfonyl chloride (0.23 ml, 2.96 mmol) 
was added under N2. The reaction mixture was stirred at room temperature for 2h. The reaction 
was diluted with DCM (30 ml), the organic layer was washed with water and brine solution, 
dried on anhydrous MgSO4, concentrated and dried under vacuum. The crude compound was 
mixed with imidazole (0.45 g, 5.86 mmol) and then heated at 70
o
C for 16 h. The crude 
compound was purified on silica gel chromatography (2% MeOH in DCM) to obtain compound 
17 as light brown liquid (370 mg, 35%).  
 
TLC  Rf = 0.4 (5% MeOH in DCM, Iodine and KMnO4 stain).  
1
H NMR (300 MHz, CDCl3) δ: 7.46 (s, 1H), 7.07 (s, 1H), 6.88 (s, 1H), 3.91 - 3.82 (m, 
1H), 3.65 (s, 3H), 2.31 - 2.24 (m, 2H), 1.77 - 1.54(m, 6H), 1.23 - 1.09 (m, 22H), 
0.91 - 0.86 (m, 3H).  
13
C NMR  (75 MHz, CDCl3) δ: 174.09, 129.41, 116.45, 58.70, 51.43, 36.30, 36.23, 33.91, 
31.85, 29.51, 29.48, 29.36, 29.25, 29.19, 28.83, 26.04, 25.88, 24.73, 22.63, 
14.07.  
MS (EI)  m/z: 364 (14.8%), 363 (21.1%), 333 (10.8%), 224(12.1%),  223 (63%), 222 
(19.5%), 221(100%), 69 (85.5%), 55(21.1%). 
HRMS  Calculated: 364.5652   Found: 364.3088. 
58 
 
Synthesis of 8-(1H-imidazol-1-yl)octadecanoic acid (18) 
 
 
 
Sodium hydroxide (0.67 g, 1.68 mmol) was added to a stirred solution of compound 17 (0.305 
g, 0.84 mmol) in a mixture of methanol (9 ml) and water (3 ml) at 0
o
C, and stirring continued 
another 3h at room temperature. Methanol was removed from mixture by evaporation. The pH
 
of reaction mixture was adjusted to 4 with 1N HCl and extracted with DCM (3 x 15 ml). The 
combined organic layers were washed with brine solution, dried on anhydrous MgSO4, and 
concentrated. The crude compound was purified by silica gel column chromatography (5% 
MeOH in DCM) to obtain compound 18 as gummy liquid (370mg, 83%).  
 
1
H NMR  (300 MHz, CDCl3) δ: 8.73 - 8.68 (m, 3H), 7.33 (s, 1H), 7.05 (s, 1H) 4.19 – 4.15 
(m, 1H), 2.32 – 2.27 (m, 2H), 1.80 - 1.54 (m, 6H) 1.33 - 1.06 (m, 22H), 0.88 – 
0.84 (m, 3H).  
13
C NMR  (75 MHz, CDCl3) δ: 131.93, 130.90, 130.78, 128.83, 128.68, 59.36, 36.20, 
36.14, 31.86, 29.52, 29.49, 29.36, 29.26, 29.17, 28.91, 28.87, 26.04, 25.89, 
24.91, 22.66, 14.10. 
MS (EI)  m/z 351 (2.8%), 350 (8.0%), 230 (14.7%), 222 (20.9%), 221 (100%), 216 
(37.8%), 215 (67.7%), 209 (60.4%), 202 (65.4%), 201 (41.1%). 
HRMS  Calculated: 350.5386   Found: 350.2936. 
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Synthesis of (3-((8-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-10-ISA) 
 
 
 
Compound 18 (225 mg, 0.643 mmol) and compound 5 (258 mg, 0.643 mmol) were dissolved in 
dry DCM then added DCC (146 mg, 0.708 mmol) at 0
o
C. The reaction mixture was stirred at 
room temperature for another 16h. The mixture was filtered and concentrated to remove the 
formed DCU. The crude compound was purified by silica gel column chromatography (5.5% 
MeOH in DCM) to obtain a gummy liquid (330 mg, 70%).  
 
TLC  Rf = 0.43 (15% MeOH in DCM, iodine and KMnO4 active).  
1
H NMR  (600 MHz, CDCl3) δ: 7.79-7.63 (m, 15H), 7.45 (s, 1H), 6.97 (s, 1H), 6.85 (s, 1H), 
4.27(m, 2H), 3.86 – 3.81 (m, 3H), 2.16 – 2.14 (m, 2H), 1.95 – 1.92  (m, 2H), 1.66 
– 1.60 (m, 4H), 1.43 – 1.41 (m, 2H), 1.21-1.13 (m, 22H), 0.99 - 0.97 (m, 2H), 
0.80 – 0.77 (m, 3H).  
13
C NMR  (151 MHz, CDCl3) δ: 173.23, 136.28, 135.21, 135.19, 135.11, 133.66, 133.59, 
133.47, 133.41, 130.61, 130.52, 130.44, 130.40, 128.85, 118.12, 117.55, 116.56, 
63.12, 63.00, 58.80, 36.23, 36.14, 33.90, 31.83, 31.79, 29.55, 29.51, 29.46, 29.43, 
29.33, 29.26, 29.20, 29.14, 28.76, 28.75, 26.00, 25.82, 24.53, 22.59, 22.20, 19.93, 
19.57, 14.07.   
MS (FAB)  m/z: 654 [M+1] (43.4%), 653 (M+, 91.9%), 603 (10.3%), 375 (12.8%), 319 
(18.3%), 303(16.2%), 289 (13.1%), 275 (18.1%), 183(20.3%), 69 (100%). 
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Synthesis of  10-(benzyloxy)decan-1-ol (20) 
 
 
 
 A stirred suspension of decane-1, 10-diol 19 (3.0 g, 17.21 mmol), benzyl bromide (2.25 ml, 
18.94 mmol) and Ag2O (5.98g, 25.82 mmol) in dry DCM (50 ml) was refluxed overnight. The 
reaction mixture filtered to remove solid Ag2O and filtrate was concentrated.  The crude product 
was purified by silica gel column chromatography (10% EtOAc in Hexane) to afford compound 
20 as gummy colorless liquid (2.96 g, 65%). 
 
TLC  Rf = 0.55 (20% EtOAC in Hexane, KMnO4 active). 
1
H NMR (300 MHz, CDCl3) δ: 7.37 – 7.28 (m, 5H), 4.52 (s, 2H), 3.60 (t, J = 6.9 Hz, 2H), 
3.49 (t, J = 6.6 Hz, 2H), 2.37 (s, 1H), 1.69 – 1.51 (m, 4H), 1.37 – 1.32 (m, 12H).   
13
C NMR   (75 MHz, CDCl3) δ: 138.65, 128.42, 128.35, 127.65, 127.49, 126.89, 72.85, 
70.52, 62.78, 32.77, 29.76, 29.58, 29.55, 29.47, 26.20, 25.80.  
MS (EI)  m/z: 264[M]
+
 (6.5%), 108 (24.9%), 107 (65.6%), 92 (37.8%), 91 (100%) .     
HRMS Calculated: 264.2089   Found: 264.2095  
 
Synthesis of 10-(benzyloxy)decanal  (21) 
 
 
 
Compound  20 (8.1g, 30.64 mmol) was dissolved in dry DCM (150 ml), and then PCC (7.86g, 
45.95 mmol) was added at 0
o
C.  The reaction mixture was stirred at ambient temperature for 2h. 
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The reaction mixture was concentrated and purified by silica gel column chromatography (10% 
EtOAC in Hexane) to give compound 21 as colorless liquid (6.27g, 78%). 
 
TLC  Rf = 0.68 (20% EtOAC in Hexane, KMnO4 active). 
1
H NMR (300 MHz, CDCl3) δ: 9.76 (t, J = 1.8 Hz, 1H), 7.39 – 7.25 (m, 5H), 4.51 (s, 2H), 
3.48(t, J = 6.6 Hz, 2H), 2.44 – 2.39 (m, 2H), 1.67-1.58 (m, 4H), 1.37-1.31 (m, 
10H).  
13
C NMR   (75 MHz, CDCl3) δ: 202.83, 138.72, 128.32, 127.59, 127.45, 72.85, 70.47, 43.88, 
29.75, 29.38, 29.35, 29.28, 29.13, 26.16, 22.06. 
MS (EI)  m/z: 262 [M]
+
 (4.1%), 108 (15.8%), 92 (31.5%), 91 (100%), 55 (11.2%). 
HRMS Calculated: 262.1933   Found: 262.1935  
 
Synthesis of 18-(benzyloxy)octadecan-9-ol (22) 
 
 
 
 1-Bromooctane (3.57 ml, 23.48 mmol) in THF (10ml) was added slowly to a stirred suspension 
of Mg metal (0.65 g, 26.83 mmol) and catalytic amount of iodine in dry THF (20 ml) at 70
o
C. 
The reaction mixture was stirred at this temperature for another 30 minutes. The Grignard 
reagent was added slowly to a stirred solution of compound 21 (4.4 g, 16.77 mmol) in THF (30 
ml) at 0
o
C and stirring continued another 2h at room temperature. The reaction was quenched 
with ammonium chloride solution, extracted with EtOAc (3 x 50 ml), combined organic layers 
were washed with brine solution, dried over MgSO4 and concentrated. The crude product was 
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purified by silica gel column chromatography (12% EtOAc in Hexane) to give compound 22 as 
low melting white color solid (3.85g, 61%).   
 
TLC  Rf = 0.45 (20% EtOAc in Hexane, KMnO4 active).  
1
H NMR (300 MHz, CDCl3) δ: 7.37 - 7.28 (m, 5H), 4.52 (s, 2H), 3.60-3.58 (m, 1H), 3.48 
(t, J = 6.6 Hz, 2H), 1.68 – 1.59 (m, 2H), 1.52 – 1.30 (m, 28H), 0.92 – 0.88 (m, 
3H).    
13
C NMR   (75.46 MHz, CDCl3) δ138.72, 128.39, 128.33, 127.62, 127.46, 125.9, 72.85, 
71.99, 70.52, 37.5, 31.9, 29.77, 29.74, 29.71, 29.61, 29.58, 29.55, 29.48, 29.30, 
26.19, 25.67, 22.68, 14.12. 
MS (EI)  m/z: 358 [M-18]
+
 (2.5%), 107 (25.5%), 92 (19.7%), 91 (100%), 69 (12.8%).   
 
Synthesis of 1-(18-(benzyloxy)octadecan-9-yl)-1H-imidazole (23) 
 
 
 
Methanesulfonyl chloride (1.64 ml) was added to a stirred solution of  compound  22 (6.0 g, 
15.93 mmol), DMAP (0.195 g, 1.59 mmol) and TEA (2.9 ml, 20.71 mmol) in dry DCM (90 ml) 
at  0
o
C. The reaction mixture was stirred at room temperature another 3h. The reaction mixture 
was diluted with DCM (100 ml), washed with 1N HCl, water, and brine solution, dried over 
anhydrous MgSO4. The crude mesylated compound and imidazole (2.17 g, 31.86 mmol) were 
heated at 70
o
C for 16h. The crude product was purified by silica gel column chromatography 
(1.5% MeOH in DCM) to give compound 23 as gummy liquid (2.22 g, 33%).     
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TLC  Rf = 0.42 (5% MeOH in DCM, KMnO4 active). 
1
H NMR (300 MHz, CDCl3) δ: 7.41 (s, 1H), 7.29 – 7.20 (m, 5H), 7.03 (s, 1H), 6.83 (s, 1H), 
4.45 (s, 2H), 3.86 – 3.77 (m, 1H), 3.41 (t, J = 6.6 Hz, 2H), 1.69 – 1.52 (m, 6H), 
1.30 – 1.28 (m, 24H), 0.86 – 0.81 (m, 3H).   
13
C NMR   (75.46 MHz, CDCl3) 138.69, 136.43, 129.39, 128.26, 127.5, 127.37, 116.30, 
72.78, 70.41, 58.59, 36.28, 31.76, 29.72, 29.38, 29.34, 29.32, 29.29, 29.17, 29.14, 
26.12, 26.02, 22.59, 14.07. 
MS (EI)  m/z :426 [M]
+
 (0.9%), 270 (5.0%), 203 (10.4%), 193 (13.7%),  105 (28.4%), 92 
(10.5%), 91 (100%), 69 (54.3%).  
HRMS  Calculated: 426.3610   Found: 426.36156 
 
Synthesis of 10-(1H-imidazol-1-yl)octadecan-1-ol (24) 
 
 
 
Compound 23 (1.5 g, 3.52 mmol) and 10% Pd on carbon (200 mg) were taken in EtOH, then it 
was hydrogenated under hydrogen balloon at reflux for 2 days. The reaction was filtered to 
remove Pd carbon and filtrate was concentrated. The crude product was purified by silica gel 
column (3% MeOH in DCM) to give compound 24 (0.96 g, 81%) as gummy liquid. 
 
TLC  Rf  =  0.55 (10% MeOH in DCM, KMnO4 and Iodine active). 
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1
H NMR (300 MHz, CDCl3) δ: 7.43 (s, 1H), 7.03 (s, 1H), 6.86 (s, 1H), 3.90 – 3.80 (m, 1H), 
3.59 (t, J = 6.9 Hz, 2H), 3.14 (s, 1H), 1.75 – 1.61 (m, 4H), 1.56 – 1.47 (m, 2H), 1.25 – 1.06 (m, 
24H), 0.86 – 0.82 (m, 3H). 
13
C NMR   (151 MHz, CDCl3) δ: 136.38, 129.18, 116.42, 62.50, 58.75, 36.28, 36.24, 32.75, 
31.75, 29.31, 29.26, 29.18, 29.13, 29.04, 26.03, 25.94, 25.71, 22.58, 14.05.  
MS (EI)  m/z : 336 [M]
+
 (4.6%), 306 (7.9%), 223 (23.3%), 221 (14.1%), 194 (14.9%), 193 
(66.8%), 123 (11%), 122 (73.9%), 105 (87.6%), 77 (56.7 %), 6 9 (100%), 55 
(32.9%).  
HRMS Calculated: 336.3141   Found: 336.31355  
 
Synthesis of 10-(1H-imidazol-1-yl)octadecanoic acid (25) 
 
 
 
Jones reagent (0.75 ml) was added to a stirred solution of compound 24 (210 mg,  0.63 mmol) in 
acetone (5 ml) and water (2.5 ml) at 0
o
C and stirring continued for 3h at room temperature. The 
reaction mixture was concentrated and diluted with water (10 ml), and extracted with DCM (3 x 
10 ml), combined organic layers were washed with brine solution, dried on MgSO4 and 
concentrated. The crude compound was purified by silica gel column (3-5% MeOH in DCM) to 
give the compound 25 (185 mg, 84%) as gummy liquid.  
 
Jones Reagent Preparation: 1 g of CrO3 was dissolved in con.H2SO4 (1 ml), then which was 
diluted with water (3 ml) at 0
o
C  
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TLC  Rf  = 0.5 (10% MeOH in DCM, KMnO4 and Iodine active).  
1
H NMR (300 MHz, CDCl3) δ: 11.23 (s, 1H), 7.69 (s, 1H), 7.12 (s, 1H), 6.88 (s, 1H), 3.94 – 
3.85 (m, 1H), 2.34 – 2.29 (m, 2H), 1.78 – 1.58 (m, 6H), 1.26 – 1.07 (m, 22H), 
0.89 – 0.74 (m, 3H). 
13
C NMR   (151 MHz, CDCl3) δ: 176.76, 136.07, 127.48, 116.65, 59.34, 41.46, 36.20, 36.15, 
34.85, 31.78, 29.70, 29.32, 29.29, 29.27, 29.26, 29.17, 29.15, 29.09, 29.06, 29.02, 
28.94, 26.03, 25.96, 25.03, 22.61, 14.09.  
MS (EI)  m/z: 336 [M]
+
 (2.7%), 238 (12.5%), 237 (67.5%), 194 (18.1%), 193 (100%), 95 
(19.8%), 69 (90.4 %), 55 (32.6%), 41 (32.7%).  
 
Synthesis of (3-((10-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-10-ISA) 
 
 
 
DCC (85 mg, 0.414 mmol) was added to a stirred solution of compound 25 (145 mg, 0.414 
mmol), compound 5 (166 mg, 0.414 mmol) and DMAP (5 mg, 0.04 mmol) in dry DCM (5 ml) at 
0
o
C under nitrogen gas. The reaction mixture was stirred at room temperature for 16h. The 
reaction mixture was filtered to remove the formed DCU and filtrate was concentrated under 
reduced pressure. The crude product was purified by silica gel column (4-5% MeOH in DCM) to 
give compound TPP-10-ISA (235 mg, 77%) as gummy liquid.   
 
TLC  Rf  = 0.45 (10% MeOH in DCM, KMnO4 and iodine active). 
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1
H NMR (300 MHz, CDCl3) δ: 7.89 – 7.66 (m, 15H), 7.54 (s, 1H), 7.07 (s, 1H), 6.92 (s, 
1H), 4.36 (t, J = 6.3 Hz, 2H), 4.05 – 3.86 (m, 3H), 2.22 (t, J = 7.5 Hz, 2H), 2.06 – 
1.94 (m, 2H), 1.73 – 1.71 (m, 4H), 1.53 – 1.48 (m, 2H), 1.26 – 1.03 (m, 22H), 
0.87 – 0.83 (m, 3H).   
13
C NMR   (75 MHz, CDCl3) δ 173.40, 135.15, 135.11, 133.78, 133.64, 130.62, 130.45, 
118.62, 117.47, 63.18, 62.95, 58.93, 36.29, 36.24, 34.08, 31.76, 29.32, 29.19, 
29.13, 29.04, 29.00, 28.95, 26.04, 25.98, 24.71, 22.58, 22.31, 22.26, 20.11, 19.41, 
14.06 . 
MS (EI)  m/z:  654 (10.7%),, 653 (23.2%), 109 (13.3%), 95 (26.5%), 83 (24.9%), 81 
(26.1%), 71 (26.4%), 69 (100%), 57 ( 68 %), 55 (84%), 43 (76.8%), 41 (68.6%).  
HRMS Calculated: 653.4230   Found: 653.42797 
 
Synthesis of 12-bromododecan-1-ol (27) 
 
 
 
Dodecane-1, 12-diol 26 (8.365 g, 42.75 mmol) , 48% HBr  in water ( 9.7 ml, 85.50 mmol) and 
toluene (120 ml) were refluxed for 3 h. The reaction mixture was concentrated, crude compound 
was dissolved in DCM (150 ml), washed with water, NaHCO3 brine solution, dried over MgSO4 
and concentrated. The crude product was purified by silica gel column (5% EtOAc in Hexane) to 
obtain compound 27 as off-white low melting solid (8.87 g, 78%)   
 
TLC  Rf = 0.55 (10% EtOAc in Hexane, KMnO4 active.) 
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1
H NMR (300 MHz, CDCl3) δ: 3.63 (t, J = 6.6 Hz, 2H), 3.40 (t, J = 6.9 Hz, 2H), 3.85 (m, 
2H), 1.59 – 1.51 (m, 2H), 1.44 – 1.27 (m, 16H).  
13
C NMR   (75 MHz, CDCl3) δ: 62.91, 34.00, 32.82, 32.74, 29.56, 29.50, 29.41, 29.22, 
28.74, 28.15, 25.73. 
MS (EI)  m/z 220 (3.6%), 164 (8.7%), 162 (8.1%), 150 (13.7%), 148 (13.6%), 97 (31.9 
%), 83 (45.4%), 82 (58.7%), 69 (66.7%), 68 (54.2%), 55 (100%), 41 (57.9%). 
HRMS  Calculated: 264.1089   Found: [M-18]
+ 
=246.09741 
 
Synthesis of 12-bromododecanal (28) 
 
 
 
 PCC (7.32 g , 33.93 mmol) was added portion wise to a stirred solution of compound 27 (6.0 g, 
22.62 mmol) in dry DCM  (90 ml) at 0
o
C, and then stirring continued at room temperature for 
another 4h. The reaction mixture was concentrated and purified by silica gel column (6% EtOAc 
in Hexane) to offere compound 28 as colorless liquid (4.3 g, 72%).  
 
TLC  Rf = 0.45 (10 EtOAc in Hexane, KMnO4 active). 
1
H NMR (300 MHz, CDCl3) δ: 9.76 (t, J = 2.1 Hz, 1H), 3.41 (t, J = 6.9 Hz, 2H), 2.42 (m, 
2H), 1.85(m, 2H), 1.63 (m, 2H), 1.44 – 1.28 (m, 14H). 
13
C NMR   (75 MHz, CDCl3) δ: 202.94, 43.88, 34.01, 32.80, 29.40, 29.36, 29.33, 29.30, 
29.19, 29.12, 29.03, 28.72, 28.58, 28.14, 24.71, 22.05. 
MS (EI)  m/z [M+1]
+
 263 (1.5%), 261 (1.6%), 220 (9.7%), 218 (13.7%), 150 (14.5%), 148 
(14.6%), 135 (10.5%). 
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Synthesis of 17-bromoheptadecan-6-ol (29) 
 
 
 
1-Bromo pentane (2.54 ml, 20.51 mmol) in THF (5 ml) was added dropwise to a stirred 
suspension of  Mg metal (0.54 g, 22.23 mmol) and catalytic amount of iodine in dry THF (15 ml) 
at 75
o
C and stirring continued another 30 minutes. The generated Grignard reagent was cooled to 
room temperature and added slowly to a stirred solution of compound 38 (4.5 g, 17.09 mmol) in 
THF (40 ml) at 0
o
C. The reaction was stirred at room temperature for 1.5 hours. The reaction 
was quenched with NH4Cl solution, extracted with EtOAc (3x50 ml), combined organic layers 
were washed with brine solution, dried on MgSO4 and concentrated. The crude compound was 
purified over silica gel column chromatography (8% EtOAc in Hexane) to give compound 29 
off-white low melting solid (3.34g, 58%). 
 
TLC  Rf = 0.54 (10 EtOAc in Hexane, KMnO4 active). 
1
H NMR (300 MHz, CDCl3) δ: 3.60 – 3.56 (m, 1H), 3.41 (t, J = 6.9 Hz, 2H), 1.85 (m, 2H), 
1.47 – 1.28 (m, 28H), 0.89 (m, 3H). 
13
C NMR   (75 MHz, CDCl3) δ: 71.98, 37.47, 37.45, 34.02, 32.83, 31.92, 29.70, 29.59, 
29.54, 29.42, 28.75, 28.17, 25.65, 25.33, 22.65, 14.05. 
MS (EI)  m/z: [M+1]
+
 263 (1.5%), 261 (1.6%), 220 (9.7%), 218 (13.7%), 150 (14.5%), 
148 (14.6%), 135 (10.5%). 
HRMS  Calculated: 264.1089   Found: [M-18]
+ 
=246.09741 
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Synthesis of 13-hydroxyoctadecanenitrile (30) 
 
 
 
Compound 29 (1.0 g, 2.98 mmol),  NaCN (175 mg, 3.58 mmol) in dry DMF were heated at 90
o
C 
for 16 hours. The reaction mixture was cooled to room temperature, and then diluted with diethyl 
ether (100 ml), organic layer was washed with cold water (3x20 ml), brine solution, dried over 
MgSO4 and concentrated. The crude product was purified over silica gel column (10% EtOAc in 
Hexane) to give compound 30 as colorless liquid (0.77 g, 92%).   
 
 TLC  Rf = 0.55 (20% EtOAc in Hexane, KMnO4 and iodine active).
 
1
H NMR (300 MHz, CDCl3) δ: 3.60 – 3.56 (m, 1H), 3.41 (m, 2H), 1.85 (m, 2H), 1.47 – 
1.28 (m, 27H), 0.92 – 0.87 (m, 3H). 
13
C NMR   (75 MHz, CDCl3) δ: 119.82, 71.88, 62.51, 37.42, 34.83, 31.91, 29.67, 29.55, 
29.48, 29.43, 29.25, 28.71, 28.61, 25.62, 25.32, 22.63, 18.88, 17.07, 14.03, 13.84. 
MS (EI)  m/z [M-18]
+
 263 (9.8%), 211 (18.6%), 210 (100%), 136 (25.5%), 122 (29.9%), 
100 (30.3%), 97(32.4%), 83 (46.2%), 55 (66.5%). 
HRMS  Calculated: 281.2719   Found: [M-18]
+ 
=263.26080 
 
Synthesis of  13-(1H-imidazol-1-yl)octadecanenitrile (31) 
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Methanesulfonyl chloride (1.3 ml, 16.78 mmol) was added to a stirred solution of compound 30 
(4.5 g, 15.99 mmol), TEA (2.9 ml, 20.78 mmol) and DMAP (0.19 g, 1.59 mmol) in dry DCM 
(70 ml) at 0
o
C under N2. The reaction mixture was stirred at room temperature for another 2h. 
The reaction mixture was diluted with DCM (100 ml), organic layer was washed with 1N HCl, 
water and brine solution, dried over MgSO4 and concentrated under reduced pressure. This crude 
compound was mixed with imidazole (2.18 g, 31.97 mmol) and heated at 70
o
C for 16 hours 
under N2. The crude product was purified by silica gel column chromatography (2% MeOH in 
DCM) to give compound 31 as light yellow liquid (1.64 g, 32 %).  
 
TLC  Rf = 0.58 (10% MeOH in DCM, KMnO4 and iodine active). 
1
H NMR (300 MHz, CDCl3) δ: 7.44 (s, 1H), 7.05 (s, 1H), 6.87 (s, 1H), 3.86 (m, 1H), 2.31 
(t, J = 7.2 Hz, 2H), 1.73 – 1.58 (m, 6H), 1.41 (m, 2H), 1.25 – 1.05 (m, 20H), 0.85 
– 0.80 (m, 3H).  
13
C NMR   (75 MHz, CDCl3) δ: 136.49, 129.37, 119.83, 116.39, 58.68, 36.30, 36.27, 31.35, 
29.34, 29.19, 29.16, 28.68, 28.59, 26.03, 25.71, 25.31, 22.3917.08, 13.91.  
MS (EI)  m/z [M]
+
 331 (3.9%), 261 (66.3%), 152 (17.4%), 151 (100%), 69 (50.5%), 55 
(20.9%), 41 (23.7%). 
HRMS Calculated: 331.2987    Found: [M-18]
+ 
=331.29944 
 
Synthesis of 13-(1H-imidazol-1-yl)octadecanoic acid (32) 
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NaOH (332 mg, 8.30 mmol) was added to a stirred solution of compound 31 (550 mg, 1.66 
mmol) in EtOH (10 ml) and water (5 ml) and the reaction mixture was refluxed for 16. The 
reaction mixture was concentrated and acidified with 1N HCl to pH 4, extracted with DCM (4 x 
30 ml), washed with brine solution, dried over MgSO4 and concentrated. The crude product was 
purified by silica gel column (4% MeOH in DCM) to give compound 32 as thick oil (470 mg, 
81%). 
 
TLC  Rf = 0.52 (10% MeOH in DCM, KMnO4  and iodine active). 
1
H NMR (300 MHz, CDCl3) δ: 9.81 (s, 1H), 8.60 (s, 1H), 7.34 (s, 1H), 7.05 (s, 1H), 4.20 – 
4.10 (m, 1H), 2.31 (t, J = 7.5 Hz, 2H), 1.85 – 1.72 (m, 4H), 1.66 – 1.59 (m, 2H), 
1.22 – 1.20 (m, 22H), 1.06 (br, 2H),  0.86 – 0.81 (m, 3H). 
13
C NMR   (75 MHz, CDCl3) δ: 177.81, 60.96, 35.76, 34.44, 31.21, 29.18, 29.13, 29.01, 
28.97, 28.90, 25.77, 25.55, 24.88, 22.32, 13.88. 
MS (EI)  m/z: 351 (2.8%), 350 (8.0%), 230 (14.7%), 222 (20.9%), 221 (100%), 216 
(37.8%), 215 (67.7%), 209 (60.4%), 202 (65.4%), 201 (41.1%). 
HRMS  Calculated: 350.5386   Found: 350.2936. 
 
Synthesis of (3-((13-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-13-ISA)  
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DCC (215 mg, 1.041 mmol) was added to a stirred solution of compound 32 (365 mg, 1.041 
mmol) and compound 5 (418 mg, 1.041 mmol) and DMAP (catalytic amount) in DCM (10 ml) at 
0
o
C under nitrogen gas and stirring continued overnight at room temperature. The reaction 
mixture was filtered and concentrated. The crude compound was purified by silica gel column 
(5% MeOH in DCM) to give compound TPP-13-ISA (600 mg, 78%) as gummy liquid. 
 
1
H NMR (600 MHz, CDCl3) δ: 7.89 – 7.84 (m, 6H), 7.82 – 7.79 (m, 3H), 7.72 – 7.69 (m, 
6H), 7.48 (s, 1H), 7.06 (s, 1H), 6.90 (s, 1H), 4.38 – 4.36 (m, 2H), 4.02 – 3.97 (m, 
3H), 2.42 (t, J = 7.8 Hz, 4H),  2.02 – 2.00 (m, 2H), 1.73 – 1.68 (m, 4H), 1.54 – 
1.52 (m, 2H), 1.25 – 1.06 (m, 22H), 0.85 – 0.82 (m, 3H). 
13
C NMR   (151 MHz, CDCl3) δ: 173.49, 135.16, 133.76, 133.70, 133.60, 130.52, 118.33, 
117.76, 68.12, 63.00, 58.83, 36.31, 36.28, 34.16, 31.37, 29.47, 29.43, 29.37, 
29.23, 29.19, 29.09, 26.07, 25.74, 24.83, 22.43, 22.28, 19.96, 19.61, 13.96. 
MS (EI)  m/z: [M+1]
+
 (16.2%), [M]
+
653 (34.5%), 183 (11.5%), 95 (15.1%), 77 (10.1%), 
69 (100.0%), 57 (18.5%), 55 (31.2%), 43 (24.2%), 41 (26.4%). 
HRMS Calculated: 653.4230    Found: 653.42199 
 
Synthesis of diethyl 2-(12-hydroxydodecyl)malonate (33) 
 
 
 
Diethylmalonate (7.52 ml, 48.316 mmol) was added to a stirred solution of compound 27 (6.54 
g, 24.658 mmol), K2CO3 (8.52 g, 61.645 mmol), KI (0.409 g, 2.466 mmol) in dry acetonitrile 
(100 ml) and heated at 90
o
C for 48h. The reaction mixture was filtered to remove the solid waste 
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and filtrate was concentrated. The crude compound was purified by silica gel column (7-10 % 
EtOAc in hexane) to give the compound 33 (5.35 g, 63%) as colorless liquid. 
 
TLC  Rf = 0.43 (30% EtOAc in Hexane, Iodine and KMnO4 active).  
1
H NMR  (300 MHz, CDCl3) δ: 4.20-4.13 (q, J = 7.2 Hz, 4H), 3.60 (t, J = 6.6 Hz, 2H), 3.29 
(t, J = 7.5 Hz, 1H), 1.87 – 1.82 (m, 2H), 1.74 (s, 1H), 1.56 – 1.49 (m, 2H), 1.28 – 
1.22 (m, 24H). 
13
C NMR  (75 MHz, CDCl3) δ: 169.59, 62.92, 61.20, 52.04, 32.75, 29.54, 29.49, 29.43, 
29.39, 29.24, 29.15, 28.69, 27.26, 25.71, 14.03. 
MS (EI)  m/z: 344 (4.7%), 173 (56.8%), 160 (100%), 55 (40.5%), 45 (47.1%), 44 (46.6%). 
HRMS  Calculated: 344.2563  Found: 344.25495  
 
Synthesis of diethyl 2-(12-oxododecyl)malonate (34) 
 
 
 
PCC (3.67g, 17.025mmol) was added portion-wise to a stirred solution of compound 33 (3.91g, 
11.35 mmol) in dry DCM (60 ml) at 0
o
C. The reaction was allowed to room temperature and 
stirring continued for another 3h. The reaction mixture was concentrated under reduced pressure 
and purified by the silica gel column (8% EtOAc in Hexane) to give the compound 34 (2.84 g, 
73%) as colorless liquid. 
 
TLC  Rf = 0.4 (20% EtOAc in Hexane, iodine and KMnO4 active). 
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1
H NMR  (300 MHz, CDCl3) δ: 9.73 (t, J = 1.8 Hz, 3H), 4.20 – 4.13 (q, J = 7.2 Hz, 4H), 
3.28 (t, J = 7.8 Hz, H), 2.42 – 2.36 (m, 2H), 1.89 -1.82 (m, 2H), 1.64 – 1.55 (m, 
2H), 1.28 – 1.26 (m, 22H)  
13
C NMR  (75 MHz, CDCl3) δ: 202.81, 169.53, 61.16, 52.01, 43.84, 29.42, 29.39, 29.32, 
29.27, 29.22, 29.13, 29.09, 28.68, 27.24, 22.02, 14.02. 
MS (FAB)  m/z: 299 (5.9%), 173 (60.9%), 133 (15.7%), 127 (10.3%), 98 (20.7%), 95 
(18.9%), 69 (23.2%), 55 (62.2%), 43 (34.2%), 41 (39.4%). 
 
Synthesis of diethyl 2-(12-hydroxyhexadecyl)malonate (35) 
 
 
 
1-Bromobutane (0.92ml, 8.512mmol) in dry THF (5ml) was added slowly to a stirred suspension 
of Mg metal (0.25g, 10.059mmol) and catalytic amount of iodine in dry THF (10 ml) at reflux 
temperature, stirred for 30 min after completion of addition. The prepared Grignard reagent was 
added drop wise to a stirred solution of compound 34 (2.65 g, 7.738 mmol) in THF (30 ml) at -
10 to -15
o
C and stirred at this temperature for 30 minutes. The reaction mixture was slowly 
warmed to room temperature and stirring continued for another one hour. The reaction was 
quenched with saturated ammonium chloride solution (10 ml), diluted with water (20 ml), 
extracted with diethyl ether (3 x 50 ml), dried on anhydrous MgSO4 and concentrated. The crude 
product is purified by silica gel chromatography (4 – 6% EtOAc in hexane) to offer compound 
35 (1.94g, 62.5%) as colorless liquid.      
 
TLC  Rf = 0.53 (20% EtOAc in Hexane, iodine and KMnO4 active).  
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1
H NMR  (300 MHz, CDCl3) δ: 4.21-4.13 (m, 4H), 3.58 – 3.54 (m, 1H), 3.29 (t, J = 7.5 Hz, 
1H), 1.88 – 1.83 (m, 2H), 1.74 (s, 1H), 1.51 – 1.22 (m, 33H), 0.89 (t, J = 6.9 Hz, 
3H). 
13
C NMR  (75 MHz, CDCl3) δ: 169.57, 71.90, 61.19, 52.04, 37.46, 37.15, 29.68, 29.58, 
29.53, 29.45, 29.26, 29.17, 28.70, 27.82, 27.28, 25.62, 22.74, 14.05. 
MS (EI)  m/z: [M – 18]+ 382 (1.5%), 343 (26.8%), 297 (14.9%), 251 (29.7%), 173 
(100.0%), 161 (15.0%), 160 (77.8%), 98 (23.0%), 87 (20.5%), 73 (19.0%), 69 
(47.6%), 55 (51.3%), 43 (26.6%), 41 (35.3%).  
 
Synthesis of diethyl 2-(12-(1H-imidazol-1-yl)hexadecyl)malonate (36) 
 
 
 
Methanesulfonyl chloride (0.36 ml, 4.587 mmol) was added slowly to a stirred solution of 
compound 35 (1.75 g, 4.369 mmol), TEA (0.79 ml, 5.679 mmol) and DMAP (53 mg, 0.437 
mmol) in dry DCM (20 ml) at 0
o
C. The reaction mixture was stirred at room temperature for 2h. 
The reaction mixture was diluted with DCM (75 ml), washed with water (50 ml), 0.5 N HCl (10 
ml) and brine solution (20 ml), dried on dry MgSO4 and concentrated. The crude compound was 
mixed with imidazole (595 mg, 8.737 mmol) and stirred at 75
o
C for 16h. The crude compound 
was purified by silica gel column chromatography (2% MeOH in DCM) to give the compound 
36 (640mg, 32.5%) as light brown color liquid. 
 
TLC  Rf = 0.63 (5% MeOH in DCM, Iodine and KMnO4 active).  
76 
 
1
H NMR  (300 MHz, CDCl3) δ: 7.44 (s, 1H), 7.04 (s, 1H), 6.86 (s, 1H), 4.19 – 4.12 (q, J = 
7.2 Hz, 4H), 3.90 – 3.80 (m, 1H), 3.27 (t, J = 7.5 Hz, 1H), 1.85 – 1.83 (m, 2H), 
1.73 – 1.64 (m, 2H), 1.26 – 1.00 (m, 29H), 0.83 – 0.78(m, 3H). 
13
C NMR  (75 MHz, CDCl3) δ: 169.54, 136.40, 129.21, 116.41, 61.17, 58.70, 52.01, 36.27, 
35.98, 29.40, 29.32, 29.22, 29.14, 28.68, 28.17, 27.25, 26.02, 22.24, 14.03, 13.82. 
MS (EI)  m/z: [M +1]
+
 (3.2%), [M]
+
 (8.7%), 405 (17.8%), 393 (26.2%), 291 (40.6%), 137 
(55.6%), 95 (23.9%), 81 (22.4%), 69 (100%), 68 (42.5%), 55 (44.3%), 41 
(40.9%). 
HRMS  Calculated: 450.3458  Found: 450.3474 
 
Synthesis of 14-(1H-imidazol-1-yl)octadecanoic acid (37) 
 
 
 
NaOH  (147 mg, 3.684 mmol) was added to a stirred solution of compound 36 (415 mg, 0.921 
mmol) in a 3:1 mixture of methanol (9 ml) and water (3 ml) at 0
o
C and stirred at room 
temperature for 3h. The reaction mixture was concentrated under reduced pressure to remove 
MeOH and adjust the pH of mixture to 5 with 1N HCl and extracted with DCM (3 x 25 ml), 
dried on anhydrous MgSO4 and concentrated under reduced pressure. The crude compound was 
obtained as light yellow color liquid. This crude compound was heated at 170
o
C to remove the 
one carboxyl acid group from di-carboxylic acid by the release of CO2. The crude product was 
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purified by silica gel column chromatography (3 to 5% of MeOH in DCM) to give the compound 
37 (221 mg, 68%) as pale yellow gummy liquid.        
TLC  Rf = 0.48 (10% MeOH in DCM, iodine and KMnO4 active).  
1
H NMR  (300 MHz, CDCl3) δ: 10.28 (s, 1H), 7.70 (s, 1H), 7.12 (s, 1H), 6.89 (s, 1H), 3.95 – 
3.85 (m, 1H), 2.33 (t, J = 7.5 Hz, 2H), 1.80 – 1.60 (m, 6H), 1.37 – 1.00 (m, 23H), 
0.85 (t, J = 7.2 Hz, 3H).  
13
C NMR  (151 MHz, CDCl3) δ: 177.89, 136.12, 127.48, 116.71, 59.36, 36.16, 35.92, 34.83,  
29.40, 29.32, 29.29, 29.26, 29.20, 29.15, 29.06, 29.06, 28.18, 25.96, 25.07, 22.30, 
22.27, 13.86.  
MS (EI)  m/z: [M]
+
 350 (1.9%), 293 (34.9%), 151 (11.4%), 138 (16.9%), 137 (55.6%), 95 
(15.6%), 69 (100%), 55 (31.5%), 43 (22.9%), 41 (30%).  
HRMS  Calculated: 350.2933   Found: 350.29349  
 
Synthesis of (3-((14-(1H-imidazol-1-yl)octadecanoyl)oxy)propyl)triphenylphosphonium 
bromide (TPP-14-ISA) 
 
 
 
DCC (104 mg, 0.502 mmol) was added to a stirred solution of compound 37 (176 mg, 0.502 
mmol), compound 5 (201 mg, 0.502 mmol) and DMAP (6 mg, 0.05 mmol) in dry DCM (10 ml) 
at 0
o
C and stirred for 16 at room temperature. The reaction mixture was filtered to remove the 
formed DCU and concentrated. The crude product was purified by silica gel column 
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chromatography (4% MeOH in DCM) to give the compound TPP-14-ISA (263 mg, 71%) as 
colorless gummy liquid. 
     
TLC  Rf = 0.35 (10% MeOH in DCM, iodine and KMnO4 active).  
1
H NMR  (300 MHz, CDCl3) δ : 7.89 – 7.66 (m, 15H), 7.49 (s, 1H), 7.06 (s, 1H), 6.90 (s, 
1H), 4.36 (t, J = 6.3 Hz, 2H), 4.05 – 3.89 (m, 3H), 2.23 (t, J = 7.5 Hz, 2H), 2.05 – 
1.96 (m, 2H), 1.76 – 1.66 (m, 4H), 1.55 – 1.50 (m, 2H), 1.31 – 1.03 (m, 22H), 
0.83 (t, J = 7.5 Hz, 3H). 
13
C NMR  (75 MHz, CDCl3) δ: 173.44, 135.13, 135.10,133.79, 133.66, 130.61, 130.44, 
118.65, 117.51, 63.17, 62.93, 58.87, 36.29, 35.99, 34.15, 29.49, 29.43, 29.37, 
29.22, 29.19, 29.09, 28.19, 26.04, 24.82, 22.27, 20.13, 19.43, 13.85.   
MS (FAB)  m/z: [M+1]
+
 654 (11.7%), 653 (24.1%), 183 (12.1 %), 95 (16.5 %), 77 (16.5%), 
69 (100%), 57 (33.2%), 43 (46%), 41 (51%).  
HRMS  Calculated: 653.4230   Found: 653.42143  
 
Synthesis of mono(2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-3-carboxy-N,N,N-
trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate) monochloride (CSE-12-IOA) 
 
 
 
Compound 3 (0.3g, 0.86 mmol) was dissolved in 5 ml of dry DCM, then one drop of dry DMF 
and oxalyl chloride (0.11ml, 1.29 mmol) were added under nitrogen atmosphere, stirred for 1h at 
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room temperature. The reaction mixture was concentrated, co-evaporated with dry chloroform (2 
x 10 ml), dried under vacuum for 1h. Carnitine hydrochloride 39 (0.153g, 0.77 mmol) in 1 ml of 
TFA was added slowly to the previously prepared acid chloride 40 and heated at 45
o
C for 16 h. It 
was cooled in ice bath, triturated with 10ml of acetone. After 2 hours the precipitated material 
was removed by centrifugation. Anhydrous ether was added drop wise to the supernatant until a 
slight cloudiness appeared, then gummy liquid was formed instead of crystals, then this was 
centrifuged.  The gummy material was washed with 3:1 ratio of diethyl ether and acetonitrile to 
give the compound CSE-12-IOA (405 mg, 81%) as dark brown gummy material.   
 
TLC Rf = 0.25 (10% water in MeOH, KMnO4 active). 
1
H NMR (600 MHz, DMSO – d6) δ: 9.25 (s, 1H), 7.93 (s, 1H), 7.20 (s, 1H), 5.47 – 5.37 (m, 
2H),  5.21 – 5.17 (m, 1H), 4.42 – 4.38 (m, 1H), 3.83 – 3.79(m, 1H), 3.65 – 3.64 
(m, 1H), 3.13 (s, 9H), 2.69 – 2.68 (m, 2H), 2.59 – 2.53(m, 1H), 2.34 – 2.29 (m, 
2H), 1.89 – 1.83 (m, 4H), 1.52 – 1.50 (m, 2H), 1.27 – 1.12 (m, 16H), 0.84 – 0.82 
(m, 2H).     
13
C NMR   (151 MHz, CDCl3) δ:  172.60, 171.00, 158.83, 158.62, 158.41, 120.95, 120.47, 
118.42, 116.44, 67.54, 65.37, 61.00, 53.44, 37.59, 34.76, 34.06, 31.43, 31.16, 
29.34, 29.30, 29.24, 29.18, 28.86, 28.83, 28.45, 25.61, 25.54, 24.57, 22.39, 14.34. 
MS (FAB+) m/z: [M
+
] 492 (37.7 %), 363 (19.1 %), 349 (15 %), 149 (22.6 %), 144 (24.2 %), 
100 (24%), 95 (25.7 %), 69 (100 %). 
HRMS Calculated: 492.3952   Found: 492.35240 
CHN analysis:  Actual value: C: 54.94 %; H: 7.41%; N: 6.86%.  
Experimental value: C: 54.32, H: 7.89%; N: 6.57%.  
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Elemental analysis result has confirmed that CSE-12-IOA is present approximately, as a salt of 
HCl and TFA in 1: 1 ratio. 
Synthesis of mono(2-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)-3-carboxy-N,N,N-
trimethylpropan-1-aminium) mono(2,2,2-trifluoroacetate) monochloride (CSE-12-ISA) 
 
 
 
 
To a stirred solution of compound 9 (0.45 g, 1.28 mmol) in 10 ml of dry DCM, cooled to 0
o
C, 
then one drop of dry DMF and oxalyl chloride (0.165 ml, 1.93 mmol) were added under nitrogen 
atmosphere and stirred  for 1h at room temperature. The reaction mixture was concentrated, co-
distilled with dry chloroform (2x15 ml), dried under vacuum for 1h. Carnitine hydrochloride 
(0.228 g, 1.16 mmol) in TFA (2 ml) was added to the acid chloride 40 and heated at 45
o
C for 
16h. The reaction was cooled in ice bath, triturated with 15 ml of acetone. After 2 hours the 
precipitated material was removed by centrifugation. Anhydrous ether was added drop wise to 
the supernatant until a slight cloudiness appeared, then gummy liquid was formed instead of 
crystals, then this was centrifuged.  The gummy material was washed with 3:1 ratio of diethyl 
ether and acetonitrile to give the compound CSE-12-ISA (620 mg, 83%) as dark brown gummy 
material.   
 
TLC Rf = 0.25 (10% water in MeOH, KMnO4 active). 
1
H NMR (600 MHz, DMSO - d6) δ: 9.27 (s, 1H), 7.91 (s, 1H), 7.75 (s, 1H), 5.49 – 5.43 (m, 
1H), 4.36 – 4.33 (m, 1H), 3.83 – 3.79 (m, 1H), 3.65 – 3.63 (m, 2H), 3.10 (s, 9H), 
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2.69 – 2.68 (m, 2H), 2.34 – 2.27 (m, 2H), 2.08 (s, 2H), 1.80 – 1.78 (m, 4H), 1.52 
– 1.49 (m, 2H), 1.25 – 1.11 (m, 21H), 0.94 – 0.93 (m, 2H),  0.84 – 0.82 (m, 3H). 
13
C NMR   (151 MHz, DMSO – d6) δ: 172.60, 171.00, 158.56, 158.53, 135.14, 133.81, 
124.36, 120.69, 120.63, 67.54, 65.38, 60.84, 53.44, 37.60, 34.05, 33.17, 31.42, 
29.38, 29.07, 28.95, 28.82, 28.46, 27.06, 25.57, 24.57, 22.40, 14.35.  
MS (FAB+) m/z:  [M+1] 495 (14.1 %), 494 (44.2 %), 144 (33.6 %), 100 (23.9 %), 85 (25.6 
%), 69 (100 %), 58 (37.4 %).  
HRMS Calculated: 494.3952   Found: 494.36024 
 
Synthesis of 2-hydroxy-4-methoxy-N,N,N-trimethyl-4-oxobutan-1-aminium iodide (41)  
 
 
 
To a stirred suspension of carnitine hydrochloride 39 (2 g, 10.12 mmol) in MeOH (30 ml), 57% 
HI in water (3 ml) was added to it and refluxed for 6h. The reaction mixture was concentrated. 
The crude compound was dissolved in acetone (20 ml) then added diethyl ether (60 ml) and 
required compound precipitated filtered and dried under vacuum. Compound 41 obtained as light 
yellow color solid (1.7 g, 55 %). 
 
TLC  Rf =0.56 (20% MeOH in DCM, Iodine, KMnO4 and ninhydrine active.) 
1
H NMR (300 MHz, DMSO-d6) δ: 5.64 – 5.62 (d, J = 6.0 Hz, 1H), 4.46 – 4.39 (m, 1H), 
3.42 – 3.32 (m, 2H), 3.15(s, 9H), 2.65 – 2.41 (m, 2H). 
13
C NMR   (75 MHz, DMSO-d6) δ: 170.87, 71.78, 69.58, 62.83, 53.90, 52.11.  
MS (EI)  m/z: [M+1]
+
 177 (9.6%),  [M]
+
 176 (100%), 59 (5.5%), 58 (11.4%).  
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HRMS Calculated:176.1281   Found: 176.12737  
 
Synthesis of 2-(((S,Z)-12-(1H-imidazol-1-yl)octadec-9-enoyl)oxy)-4-methoxy-N,N,N-
trimethyl-4-oxobutan-1-aminium iodide (CDE-12-IOA) 
 
 
 
DCC (89 mg, 0.43 mmol) was added to a stirred solution of compound 3 (150 mg, 0.43 mmol) 
compound 41 (130 mg, 0.43 mmol), and DMAP (3 mg) in DCM (10 ml) at 0
o
C. The reaction 
was stirred at RT for 16h, filtered off the formed DCU and concentrated. The crude product was 
purified by basic alumina column (3-4% MeOH in DCM) to give the compound 51 (187 mg, 
69%) as very thick gummy liquid.  
 
TLC  Rf =0.35 (15% MeOH in DCM, iodine, KMnO4 and ninhydrin active.) 
1
H NMR (300 MHz, DMSO -d6) δ 7.59 (s, 1H), 7.19 (s, 1H), 6.85 (s, 1H), 5.52 – 5.46 (m, 
1H), 5.38 – 5.30 (m, 1H), 5.20 – 5.12 (m, 1H), 4.21 – 4.00 (m, 1H), 3.85 – 3.71 
(m, 2H), 3.67 (s, 3H), 3.09 (s, 9H), 2.79 – 2.77 (m, 2H), 2.51 -2.49 (m, 2H), 2.46-
2.38 (m, 2H), 2.35 – 2.29 (m, 2H), 1.88 (s, 2H),1.76 – 1.68 (m, 2H), 1.53 – 1.48 
(m, 2H), 1.27 – 1.17 (m, 15H), 0.97 – 0.91 (m, 1H), 0.80 (m, 3H). 
13
C NMR   (75 MHz, DMSO-d6) δ: 172.55, 169.88, 137.08, 132.60, 128.80, 125.61,  117.56, 
67.35, 65.16, 57.76, 53.53, 52.29, 37.35, 35.18, 34.02, 31.54, 29.32, 29.02, 28.93, 
28.77, 28.62, 27.10, 25.86, 24.53, 22.40, 14.34. 
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MS (EI)  m/z: [M+1]
+
 507 (22.6%), [M]
+
 506 (68.2%), 158 (34.1%), 99 (100%), 95 
(25.1%), 83 (24.9%), 69 (100%), 59 (35.4%), 58 (53%), 55 (46.4%), 41 (33.5%). 
HRMS  Calculated: 506.3952   Found: 506.38453  
 
Synthesis of 2-((12-(1H-imidazol-1-yl)octadecanoyl)oxy)-4-methoxy-N,N,N-trimethyl-4-
oxobutan-1-aminium iodide (CDE-12-ISA) 
 
 
 
DCC (118 mg, 0.57 mmol) was added to a stirred solution of compound 8 (200 mg, 0.57 mmol) 
compound 41 (173 mg, 0.57 mmol) and DMAP (4 mg) in dry DCM (10 ml) and stirring 
continued at room temperature for 16. The reaction mixture was filtered to remove formed DCU 
and concentrated. The crude compound was purified by basic alumina column (3-4% MeOH in 
DCM) to offered compound CDE-12-ISA (236 mg, 65%) as thick gummy liquid. 
 
TLC  Rf =0.32 (15% MeOH in DCM, KMnO4, iodine and ninhydrin active.) 
1
H NMR (300 MHz, DMSO-d6) δ 7.61 (s, 1H), 7.16 (s, 1H), 6.88 (s, 1H), 5.51 (m, 1H), 
4.04 – 3.94 (s, 1H), 3.84 – 3.73 (m, 2H), 3.62 (s, 3H), 3.13 – 3.09 (s, 9H), 2.79 – 
2.76 (m, 2H), 2.34 – 2.28 (m, 2H), 1.70 – 1.63 (m, 4H), 1.52 – 1.48 (m, 2H), 1.2 – 
1.17 (m, 21H), 0.94 – 0.92 (m, 2H), 0.82 (m, 3H). 
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13
C NMR   (75 MHz, DMSO-d6) δ: 172.55, 169.88, 137.20, 128.94, 117.35, 67.36, 65.15, 
57.71, 53.53, 52.27, 37.34, 35.87, 34.01, 31.56, 29.32, 29.26, 29.10, 28.96, 28.79, 
28.63, 25.90. 
MS (EI)  m/z: [M+1]
+
 509 (14.5%), [M]
+
 508 (44.1%), 158 (22.6%), 99 (48.0%), 83 
(18.7%), 69 (100%), 59 (22.6%), 58 (31.7%), 55 (27.2%), 41 (21.7%). 
HRMS  Calculated: 508.3952   Found: 508.40062  
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